

ESC Spotlight

Local Indian Edition Comprising of

European Heart Journal Supplements |

European Heart Journal Cardiovascular Pharmacotherapy |

European Heart Journal Case Reports | Cardiovascular Research |

European Heart Journal Quality of Care and Clinical Outcomes

Member
of the ESC
Journal
Family





In **Uncontrolled Hypertension** with **High CV risk**

^{Rx} **Telma-CT** ⁴⁰/₈₀

Telmisartan 40/80 mg + Chlorthalidone 6.25/12.5 mg

Tackle CV Risk, ACT Now!

The Legacy Effect that prevents



1 in 2
HF admission



1 in 3
stroke cases



1 in 4 overall
CHD cases

Abbreviated Prescribing Information:

Telma CT Active Ingredients: Telma CT 40/6.25, 80/6.25, 40/12.5, 80/12.5 mg - Each uncoated bilayer tablet contains: Telmisartan 40 mg or 80 mg and chlorthalidone 6.25 or 12.5 mg. **Indication:** For the treatment of essential hypertension. Telma CT can be used as initial therapy in patients likely to need multiple antihypertensive agents. **Dosage and Administration:** Patient with no adequate control of blood pressure either with telmisartan or chlorthalidone monotherapy can be shifted to Telma CT. Telma CT can be used as initial therapy if the patient is more likely to need multiple drugs to achieve blood pressure target. **Contraindications:** Known hypersensitivity to telmisartan or chlorthalidone, patients with anuria, pregnant and lactating females. **Warning and Precautions:** Caution required in hepatic impairment, and in volume depleted patients. Hyperuricemia may occur or frank gout may be precipitated. **Use in Pregnancy & Lactation:** For telmisartan pregnancy category is C for first trimester and D for second and third trimester. Excretion in human milk is unknown. With thiazides, there is risk of fetal and neonatal jaundice, and thrombocytopenia. Telma CT should be discontinued immediately if the patient becomes pregnant. **Adverse Drug reactions:** Headache, dizziness, asthenia, hypotension, cough, nausea, upper respiratory tract infection, weakness, anorexia, gastric upset, cramping, etc.

ABPI Ref: Telma CT /1-Jan-2022

For further product related query, contact at Glenmark Pharmaceuticals Limited (GPL), Medical Services, Corporate Enclave, B. D. Sawant Marg, Chakala, Andheri (E), Mumbai - 99. E mail id: GlobalCustomerService@glenmarkpharma.com For any Adverse Event or Product Quality Complaint related to Glenmark marketed products, contact on GlobalCustomerService@glenmarkpharma.com

For the use of Registered Medical Practitioner or Hospital or a Laboratory only

ZOLTANMAX
A Division of **glenmark**

PV/CODE: TELMACT/ADVERT/16052022/1030

European Heart Journal

Case Reports

EDITOR-IN-CHIEF

A. John Camm
St George's University of London, UK

ASSISTANT EDITOR

C. Fielder Camm
University of Oxford, UK

DEPUTY EDITORS

Monika (née Aržanauskaitė) Radikė
Liverpool Heart and Chest Hospital
Nikolaos Bonaros
University Hospital Innsbruck, Germany
Jonathan M Behar

DEPUTY EDITORS

Royal Brompton Hospital, London, UK
Elena Cavarretta
University of Rome La Sapienza, Italy
Domenico D'Amario
Policlinico Universitario Agostino Gemelli, Italy
Amardeep Dastidar
Bristol Heart Institute, UK
Tom De Potter
OLV Hospital Aalst, Belgium
Borislav Dinov
Heart Centre Leipzig, Germany
Georg Golasch
Medical University of Vienna, Austria
Brian Halliday
Royal Brompton Hospital, London, UK
Riccardo Liga
University of Pisa, Italy
Danny van de Sande
University Medical Center Utrecht,
The Netherlands

Gianluigi Savarese
Karolinska Institute, Stockholm, Sweden
Asad Shabbir
Queen Mary University of London, Barts and The London
School of Medicine and Dentistry, UK
Christoph Sinning
Universitätsklinikum Hamburg Eppendorf Universitar-
esHerzzentrum Hamburg GmbH, Germany
Philipp Sommer
Herz- und Diabeteszentrum Nordrhein-Westfalen
Timothy Tan
Westmead and Auburn Hospitals, Sydney, Australia
Ross Thomson
Barts Heart Centre, London, UK
Inga Voges
Universitätsklinikum Schleswig-Holstein, Germany

ASSOCIATE EDITORS

Mark Abela
Mater Dei Hospital, Malta
Mohammed Al-Hijji
Heart Hospital, Hamad Medical Cooperation, Qatar
@alhijjim
Richard Ang
Homerton University Hospital NHS Foundation
Trust, UK
Diego Araiza-Garaygordobil
National Institute of Cardiology "Ignacio Chávez",
Mexico
Luca Arcari
University of Rome La Sapienza, Italy
Patrick Badertscher
University Hospital Basel, Switzerland
Constantinos Bakogiannis
Aristotle University of Thessaloniki, Greece
Enache Bogdan
Centre HospitalierPrincesse Grace, Monaco
Daniel Bromage
King's College London, UK
F.AayshaCader
Ibrahim Cardiac Hospital, Bangladesh
Milenko Cankovic
Institute of Cardiovascular Diseases of Vojvodina,
Serbia
Ruben Casado Arroyo
Université Libre de Bruxelles, Belgium
Silvia Castelletti
Istituto Auxologico Italiano IRCCS, Milan, Italy
GokselCinier
Kackar State Hospital, Turkey
Edoardo Conte
Centro CardiologicoMonzino IRCCS, Milan, Italy
Michel Corban
Mayo Clinic, Minnesota, USA
Marta Cvijic
University Medical Centre Ljubljana, Slovenia
Romain Didier
CHU de la Cavale Blanche, France
David Duncker
Hannover Medical School, Germany
Anastasia Egorova
Leiden University Medical Center, Netherlands
Parham Eshtehardi
Emory University School of Medicine, USA
Giulia Ferrannini
Karolinska Institute, Sweden
Farshad Forouzanmehr
Case Western Reserve University, Ohio, USA
Jalaj Garg
Medical College of Wisconsin, Wisconsin, USA
Livia Gheorghe
Puerta del Mar Hospital, Spain

Belinda Gray
Royal Prince Alfred Hospital, Australia
Ying Gue
East and North Hertfordshire NHS Trust, UK
Suzan Hatipoglu
Royal Brompton Hospital, UK
Zaid Iskandar
Ninewell Hospital and Medical School, UK
Christoph Jensen
Marienhospital Gelsenkirchen, Germany
Grigoris Karamasis
Essex Cardiothoracic Centre, UK
Antonios Karanasos
University of Athens, Hippokration Hospital, Greece
Tina Khan
Harefield Hospital, UK
Takeshi Kitai
Kobe City Medical Center General Hospital, Japan
Harry Klimis
University of Sydney, Australia
Attila Kovács
Semmelweis University, Budapest, Hungary
Sylvia Krupickova
Royal Brompton Hospital, UK
Luke Laffin
Cleveland Clinic, Ohio, USA
Roberto Lorusso
Maastricht University Medical Centre, Netherlands
Nidhi Madan
Rush University Medical Center, Illinois, USA
Costantino Mancusi
Federico II University of Naples, Italy
Massimo Mapelli
University of Milan, Italy
Marcelo Miglioranza
Cardiovascular Imaging Research Lab, Avenida Princesa Isabel,
Brazil
Francesco Moroni
Università Vita-Salute San Raffaele, Italy
Francesca Musella
Royal Brompton Hospital, UK
Prashant Nagpal
University of Iowa Hospitals and Clinics, Iowa, USA
Akhil Narang
Northwestern University, Illinois, USA
David Niederseer
University Hospital Zurich, Switzerland
Dan Nistor
Institute for Cardiovascular Diseases and Transplant, Romania
David Oxenburgh
Liverpool John Moores University, UK
Elizabeth Paratz
St Vincent's Hospital Melbourne, Australia
Rita Pavasini
Azienda Ospedaliero-Universitaria di Ferrara, Italy

Pierpaolo Pellicori
University of Glasgow, UK
Michel Pompeu Sá
Division of Cardiovascular Surgery - PROCAPE/UPE, Brazil
Filippo Puricelli
Royal Brompton Hospital, London
Sadaf Raza
Manchester University NHS Foundation Trust, UK
Zahra Raisi-Estabragh
Queen Mary University of London, UK
Piotr Rudziński
The Cardinal Stefan Wyszyński Institute of Cardiology, Poland
Giulio Russo
Università Cattolica del Sacro Cuore, Fondazione Policlinico A
Gemelli IRCCS, Italy
Maria Sanz de la Garza
Hospital Clinic Barcelona, Spain
Robert Schoenbauer
Landeskrankenhaus Wiener Neustadt, Austria
Sameh Shaheen
Ain Shams University School of Medicine, Egypt
Ching-Hui Sia
National University of Singapore, Singapore
Arvind Singh
Madras Medical Mission Institute of Cardio Vascular Diseases, India
HelleSoholm
Blegdamsvej 9, Copenhagen, Denmark
Sabato Sorrentino
Magna Graecia University, Italy
Michael Spartalis
3rd Department of Cardiology, National and Kapodistrian University
of Athens, Athens, Greece
Konstantinos Stathogiannis
National and Kapodistrian University of Athens, Greece
Davide Stolfo
Azienda Ospedaliero-Universitaria Ospedali Riuniti di Trieste, Italy
Dimitrios Terentes-Printzios
Oxford University Hospitals NHS Foundation Trust, UK
Erica Turr
Manchester, UK
Danny van de Sande
Utrecht University, The Netherlands
Christophe Vandenbriele
University Hospitals, Leuven, Belgium
Andrew Vanezis
Nottingham City Hospital, UK
Poonam Velagapudi
University of Nebraska Medical Center, Nebraska, USA
Dimitrios Vrachatis
Humanitas Clinical and Research Hospital, Italy
Christopher Wong
University of Adelaide and Royal Adelaide Hospital, Australia
Rami Rizi Yousef Abumuaileq
Palestinian Medical Services, Palestine

Cardiovascular Research

academic.oup.com/cardiovascres

EDITOR-IN-CHIEF

Tomasz J. Guzik
Institute of Cardiovascular and Medical
Sciences, University of Glasgow, UK

DEPUTY EDITORS

Charalambos Antoniades
Division of Cardiovascular Medicine, Radcliffe
Department of Medicine, University of
Oxford, UK
Andrew Baker
Centre for Cardiovascular Science, University
of Edinburgh, UK
Karlheinz Peter
Baker Heart and Diabetes Institute,
Melbourne, Australia
Eva van Rooij
Hubrecht Institute, Utrecht, Netherland

REVIEWS DEPUTY EDITOR

Ali J. Marian
The University of Texas Health Science
Center-Houston, Texas

EXECUTIVE DEPUTY EDITORS

Christopher Loughrey
Institute of Cardiovascular and Medical
Sciences, University of Glasgow, UK
Stuart Nicklin
Institute of Cardiovascular and Medical
Sciences, University of Glasgow, UK
Pasquale Maffia
Institute of Institute of Infection, Immunity &
Inflammation, University of Glasgow, UK

EDITORIAL OFFICE

Senior Managing Editor

Sarah K. Brown
Cardiovascular.Research@glasgow.ac.uk
Glasgow, UK

Assistant Editor

Sean McLeod

Editorial Administrator

Adam M. Sheikh

SENIOR ADVISING EDITORS

Barbara Casadei, UK
Anna Dominiczak, UK
Goran Hansson, Sweden
Peter Libby, USA
Joseph C. Wu, USA
Salim Yusuf, Canada

PAST EDITORS-IN-CHIEF

Karin R. Sipido
Belgium
Hans Michael Piper
Germany*
David Garcia-Dorado
Spain*
Michiel J. Janse
Netherlands
David J. Hearse
UK
Peter Sleight
UK
*co-Editors-in-Chief

ASSOCIATE EDITORS

Elena Aikawa, USA
Johann Bauersachs, Germany
Erik Biessen, Netherlands
Lothar Blatter, USA
Giuseppina Caligiuri, France
Daniela Carnevale, Italy
Elisabetta Cerbai, Italy
Sean Davidson, UK
Christian Delles, UK
Grant Drummond, Australia
Annarita Di Lorenzo, USA
Jie Du, China
Dirk Duncker, Netherlands
Jeanette Erdmann, Germany
Paul Evans, UK
Loren Field, USA
Ingrid Fleming, Germany
Mauro Giacca, Italy
Derek Hausenloy, Singapore
Emilio Hirsch, Italy
Imo Hofer, Netherlands
Meena S. Madhur, USA
Lars Maegdefessel, Germany
Manuel Mayr, UK
Dominik Müller, Germany
Stanley Nattel, Canada
Giuseppe Danilo Norata, Italy
Carol Ann Remme, Netherlands
Paul Riley, UK
Judith Sluimer, Netherlands
Kurt Stenmark, USA
Johann Wojta, Austria
Seppo Ylä-Herttuala, Finland
Wolfram Zimmermann, Germany

GUEST EDITOR

Thomas F. Lüscher, UK

CONSULTING EDITORS

Lina Badimon, Spain
Keith Channon, UK
Francesco Cosentino, Sweden
Steven Houser, USA
David Eisner, UK
Litsa Kranias, USA
Giuseppe Lembo, Italy
Ziad Mallat, UK
Federica Marelli-Berg, UK
Henning Morawietz, Germany
Elizabeth Murphy, USA
Ryozo Nagai, Japan
Matthias Nahrendorf, USA
Jeremy D. Pearson, UK
Ajay Shah, UK
Godfrey Smith, UK
Alain Tedgui, France
Christian Weber, Germany

JOINT EDITORS WITH EUROPEAN HEART JOURNAL

Giovanni G. Camici
Claudia Monaco
Thomas Thum

ONLINE EDITORIAL TEAM

Charalambos Antoniades
Adam M. Sheikh
Sarah K. Brown

ESC JOURNALS TWITTER AMBASSADORS FOR CARDIOVASCULAR RESEARCH

Michael Drozd
W. Glen Pyle

ESC JOURNAL FAMILY ETHICS COMMITTEE

Mat Daemen
Kim M. Fox
Ursula Ravens
Maarten L. Simoons
Christian Hamm

EDITORIAL BOARD

- Giuseppe Ambrosio
University of Perugia, Italy
- Alexios Antonopoulos
Athens Medical School, Greece
- Ioanna Andreadou
National and Kapodistrian University of Athens, Greece
- Reza Ardehali
UCLA, USA
- Metin Avkiran
The Rayne Institute, St Thomas' Hospital, UK
- Jean-Luc Balligand
Université catholique de Louvain, Belgium
- Colin Berry
University of Glasgow, UK
- Christoph J. Binder
Medical University of Vienna, Austria
- Alex Bobik
Baker Heart and Diabetes Institute, Australia
- Jes-Niels Boeckel
Leipzig University, Germany
- Reinier Boon
Goethe University, Germany
- George W. Booz
University of Mississippi Medical Center, USA
- Chantal Boulanger
INSERM, Paris Cardiovascular Research Center, France
- Angela Bradshaw
University of Glasgow, UK
- Ralf Brandes, Goethe-University, Germany
- Ana Briones
Universidad Autónoma de Madrid, Spain
- Gianluigi Condorelli
Humanitas University, Italy
- Daniel Conklin
University of Louisville, USA
- Ruben Coronel
Academic Medical Center, University of Amsterdam, Netherlands
- Murray Clarke
University of Cambridge, UK
- Salvatore Cuzzocrea
University of Messina, Italy
- Mat J.A.P. Daemen
Amsterdam UMC, University of Amsterdam, Netherlands
- Andreas Daiber
University Hospital Mainz, Germany
- Jan Danser
Erasmus MC, Netherlands
- Leon de Windt
Maastricht University, Netherlands
- Mirela Delibegovic
University of Aberdeen, UK
- Christopher Denning
University of Nottingham, UK
- Fabio Di Lisa
University of Padua, Italy
- Javier Diez
University of Navarra, Spain
- Stefanie Dimmeler
Goethe University, Germany
- Dobromir Dobrev, University Duisburg-Essen, Germany
- Agnieszka Dobrzyn
Polish Academy of Sciences, Poland
- Arnold von Eckardstein
Universität Zürich, Switzerland
- Øyvind Ellingsen
Norwegian University of Science and Technology, Norway
- Costanza Emanueli
Imperial College London UK
- Thomas Eschenhagen
University Medical Center Hamburg Eppendorf, Germany
- Larissa Fabritz
University of Birmingham, UK
- Peter Ferdinandy
Semmelweis University, Hungary
- Gemma Figtree
University of Sydney, Australia
- Stefan Frantz
University Hospital Würzburg, Germany
- Keiichi Fukuda
Keio University School of Medicine, Japan
- David Fulton
Augusta University, USA
- Zbigniew Gaciong
Medical University of Warsaw, Poland
- Elena Galkina
Eastern Virginia Medical School, USA
- Pingjin Gao
Jiaotong University School of Medicine and Shanghai Institute of Hypertension, China
- Meinrad Gawaz
Eberhard Karls University, Germany
- Christopher George
Swansea University Medical School, UK
- Sarah J. George
Bristol Heart Institute, Bristol Royal Infirmary, UK
- Jonathan Golledge
James Cook University, USA
- Ana M. Gomez
INSERM, Université de Paris Sud, France
- Kathy Griendling
Emory University, USA
- Asa Gustafsson
University of California, San Diego, USA
- Stephane Hatem
INSERM, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière; ICAN: Institut de Cardiometabolisme et Nutrition, France
- Anthony M
Heagerty, University of Manchester, UK
- Deborah J
Henderson, Newcastle University, UK
- Gerd Heusch
Universitätsklinikum Essen, Germany
- Denise Hilfiker-Kleiner
Hannover Medical School, Germany
- Marcel van der Heyden
Utrecht University, Netherlands
- Joseph Hill, UT Southwestern, USA
- Yu Huang
Chinese University of Hong Kong, China
- Yoshihiro Ishikawa
Yokohama City University, Japan
- Hiroshi Itoh
Keio University, Japan
- Frederic Jaissier
INSERM Centre de Recherche des Cordeliers, France
- Jason Johnson
Bristol Medical School, UK
- Thomas Kahan
Karolinska Institute, Sweden
- Elissavet Kardami
University of Manitoba, Canada
- Christopher Kevil
LSU Health Sciences Center, USA
- Richard Kitsis
Albert Einstein College of Medicine, USA
- Andre G. Kleber
Harvard Medical School, USA
- Mark Kohr
Johns Hopkins University, USA
- Yoshihiro Kokubo
National Cerebral and Cardiovascular Centre, Japan
- Wei Kong
Peking University, China
- Jason Kovacic
Victor Chang Cardiac Research Institute, Australia
- Patrick Lacolley
INSERM, Université de Lorraine, France
- Pablo Lamata
Kings' College London, UK
- Ulf Landmesser
Charité Universitätsmedizin Berlin, Germany
- Roberto Latini
IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Italy
- Ulrich Laufs
Universitätsklinikum Leipzig, Germany
- James Leiper
University of Glasgow, UK
- Gregory Lip
University of Birmingham, UK
- George Liu
Peking University, China
- William E. Louch
Oslo University Hospital, Norway
- Kathy Lui
Chinese University of Hong Kong, China
- Esther Lutgens
Ludwig Maximilian's University (LMU), Netherlands
- Angela Maas
Radboud University Nijmegen Medical Centre, Netherlands
- Mandy MacLean
University of Strathclyde, UK
- Kenneth Macleod
Imperial College London, UK
- Rosalinda Madonna
University of Pisa; The University of Texas Health Science Center at Houston, Italy
- Maciej Malecki
Jagiellonian University Medical College, Poland
- Francine Marques
Monash University, Australia
- Alicia Mattiazi
Universidad Nacional de La Plata, Argentina
- Pál Maurovich-Horvat
Semmelweis University, Budapest
- Philippe Menasché
Université Paris Descartes, France
- Daphne Merkus
Erasmus MC University Medical Centre Rotterdam, Netherlands
- Joseph Miano
Augusta University, USA
- Jean-Baptiste Michel
UMR 1148, Inserm-Paris University, Xavier Bichat Hospital, France
- Evangelos Michelakis
University of Alberta, Canada
- Augusto Montezano
University of Glasgow, UK
- Thomas Muenzel
University Medical Center Mainz, Germany
- Rachel Myles
University of Glasgow, UK
- Andrew C. Newby
Bristol University, UK
- Antonio Nicoletti
INSERM, University Denis Diderot, France

EDITORIAL BOARD

Tobias Opthof
Amsterdam UMC Academic Medical
Center, Netherlands

Patrick J. Pagano
University of Pittsburgh, USA

Zoltan Papp
University of Debrecen, Hungary
Axel Pries, Charité Universitätsmedi-
zin, Germany

Peter Psaltis
University of Adelaide, Australia
Marlene Rabinovitch, Stanford
University, USA

Ursula Ravens
TU Dresden; University of Freiburg,
Germany

Carol Ann Remme
Amsterdam UMC, Academic Medical
Center, Netherlands

Llewelyn Roderick
KU Leuven, UK

Andrew Sage
University of Cambridge, UK

Maurilio Sampaolesi
KU Leuven, Belgium

Gaetano Santulli
Albert Einstein College of Medicine,
USA

Gabriele Schiattarella
University of Texas Southwestern
Medical Center, USA

Richard Schulz
University of Alberta, Canada

Sebastiano Sciarretta
Sapienza University of Rome, Italy

Mateusz Siedlinski
Jagiellonian University Medical
College, Poland

Nicola Smart
University of Oxford, UK

Christopher Sobey
La Trobe University, Australia

Oliver Soehnlein
Institute for Cardiovascular Prevention
(IPEK); German Center for Cardiovascular
Research (DZHK), Germany

Derek Steele
University of Leeds, UK

Charles Steenbergen
John Hopkins University, USA

Konstantinos Stellos
Newcastle University, UK

Duncan Stewart
University of Ottawa, Canada

Roland Stocker
Victor Chang Cardiac Research Institute,
Australia

Mark Sussman
San Diego State University, USA

Alain Tedgui
INSERM, Université de Paris, France

Cesare Terracciano
Imperial College London, UK

Maciej Tomaszewski
University of Manchester, UK

Dimitris Tousoulis
National and Kapodistrian University of
Athens, Greece

Marcel Van der Hayden
Utrecht University, Netherlands

Jolanda van der Velden
VU University Medical Center, Netherlands

Jamie Vandenberg
Victor Chang Cardiac Research Institute,
Australia

Richard S. Vander Heide
LSU Health New Orleans, USA

Andras Varro
University of Szeged, Hungary
Renee Ventura-Clapier
Université Paris-Sud, France

Gemma Vilahur
Hospital de la Sant Pau, Spain

Johannes Waltenberger
University of Münster, Germany

Xin Wang
University of Manchester, UK

Jeremy P.T. Ward
King's College London, UK

Joanna Wardlaw
University of Edinburgh, UK

Neal Weintraub
Augusta University, USA

Paul Welsh
University of Glasgow, UK

Jolanda Wentzel
Erasmus University Medical Centre, Netherlands

Philip Wenzel
University Medical Center Mainz, Germany

Cornelia Weyand
Stanford University School of Medicine, USA
Lorraine Work, University of Glasgow, UK

Rui-ping Xiao
Peking University, China

Ying Yu
Tianjin Medical University, China

Manuela Zaccolo
University of Oxford, UK

Alma Zernecke
Universitätsklinikum Würzburg, Germany

Andreas Zirlik
Medizinische Universität Graz, Germany

European Heart Journal - Cardiovascular Pharmacotherapy

academic.oup.com/ehjcvp

EDITOR-IN-CHIEF

Stefan Agewall
Institute of Clinical Medicine,
Oslo University, Oslo, Norway

ASSOCIATE EDITORS

Keld Kjeldsen
Copenhagen University Hospital (Amager-
Hvidovre) and Aalborg University, Denmark

Basil Lewis
Lady Davis Hospital, Carmel Medical Center,
Haifa, Israel

Christopher Granger
Duke University, USA

Koji Hasegawa
National Hospital Organization Kyoto
Medical Center, Kyoto, Japan

Takeshi Kimura
Kyoto University Graduate School of
Medicine, Japan

Giuseppe Rosano
St George's Hospitals NHS Trust University
of London, UK

Juan Tamargo
Universidad Complutense, Madrid, Spain

Jeff Washam
Duke University, USA

SOCIAL MEDIA EDITOR

Gianluigi Savarese
Karolinska Institutet, Stockholm, Sweden

EDITORIAL BOARD

Stephan Achenbach
University of Erlangen, Germany

Angeles Alonso
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain

Jane Armitage
Clinical Trial Service Unit (CTSU), University of
Oxford, Oxford, UK

Dan Atar
Oslo University Hospital, Oslo, Norway

Sang Hong Baek
The Catholic University of Korea,
South Korea & St. Mary's Hospital, Seoul, South
Korea

C. Noel Bairey Merz
Barbra Streisand Women's Heart Center,
Cedars-Sinai Heart Institute, Los Angeles, USA

Jeroen J Bax
Leiden University Medical Center, Leiden, The
Netherlands

John Beltrame
University of Adelaide, Adelaide, Australia

Deepak L. Bhatt
Harvard Medical School, Boston, USA

Vera Bittner
University of Alabama at Birmingham, Alabama,
USA

Louise Bowman
Nuffield Department of Population Health,
University of Oxford, Oxford, UK

EDITORIAL BOARD

Eugene Braunwald
Brigham & Women's Hospital, Boston, USA

Alida LP Caforio, University of Padova, Padova, Italy

John Camm
St George's University of London, London, UK

Claudio Cecconi
University of Ferrara, Ferrara, Italy

Robin Choudhury
Oxford University, Oxford, UK

Renata Cifkova
Thomayer Teaching Hospital, Prague, CZ

Raffaele De Caterina
Ospedale SS. Annunziata, Chieti, Italy

Gheorghe-Andrei Dan
Colentina University Hospital, Bucharest, Romania

Geneviève Derumeaux, Institut Mondor de Recherche
Biomedicale, Paris, France

Dobromir Dobrev
University Duisburg-Essen, Essen, Germany

Robert Doughty
University of Auckland, Auckland, New Zealand

Heinz Drexel
Schwerpunkt Krankenhaus Feldkirch, Feldkirch, Austria

Morten Wang Fagerlund
Oslo University, Oslo, Norway

Gerasimos Filippatos
Athens University Hospital, Athens, Greece

Wolfgang-Michael Franz
Ludwig-Maximilians-University, Munich, Germany

Keiichi Fukuda
Keio University School of Medicine, Tokyo, Japan

Christian Funck-Brentano
Pitié-Salpêtrière University Hospital, Paris, France

Bernard Gersh
Mayo Clinic, Rochester, USA

Evangelos Giannitsis
University of Heidelberg, Heidelberg, Germany

Robert P Giugliano
Brigham and Women's Hospital, Boston, US

Shinya Goto, Tokai University School of Medicine,
Tokyo, Japan

Stefan Hohnloser
Klinikum der J.W. Goethe-Universität, Frankfurt,
Germany

Dayi Hu
People's Hospital of Peking University, Beijing, China

Stefan James
Uppsala Clinical Research Center, Uppsala, Sweden

Ewa Jankowska
Wrocław Medical University, Wrocław, Poland

Juan Carlos Kaski
St George's University of London, London, UK

John J.P. Kastelein
University of Amsterdam, Amsterdam,
The Netherlands

Paulus Kirchhof
Institute of Cardiovascular Sciences, University of
Birmingham, Birmingham, UK

Sverre Kjeldsen
Ullevaal University Hospital, Oslo, Norway

Maddalena Lettino
Humanitas Research Hospital, Milano, Italy

A Michael Lincoff MD
Cleveland Clinic, Cleveland, OH

Gregory Lip
City Hospital Birmingham, Birmingham, UK

Leonardo De Luca, Department of Cardiosciences,
San Camillo-Forlanini, Rome, Italy

Julinda Mehilli
Department of Internal Medicine I, University of
Munich, Germany

Chiara Melloni
Duke University School of Medicine, North Carolina,
USA

EDITORIAL BOARD

Eliano Pio Navarese
Heinrich-Heine-Universität Dusseldorf, Dusseldorf, Germany

Alexander Niessner
Medical University of Vienna, Vienna, Austria

Koichi Node
Saga University, Saga, Japan

Michelle L O'Donoghue MD, Harvard Medical
School Cardiovascular Division, Brigham and
Women's Hospital, Boston, MA

Pasquale Perrone-Filardi
University of Naples, Naples, Italy

Fausto Pinto
Lisbon Cardiovascular Institute, Lisbon, Portugal

Bertram Pitt
University of Michigan, Ann Arbor, USA

Silvia Priori
Fondazione Salvatore Maugeri, University of
Pavia, Pavia, Italy

Harmony Reynolds
NYU Langone Medical Center, New York, USA

Bianca Rocca
Catholic University School of Medicine, Rome,
Italy

Luis Ruilope
Hospital 12 de Octubre, Madrid, Spain

Marc S
Sabatine, Brigham and Women's Hospital, Boston,
USA

Raul Santos
University of Sao Paulo, Sao Paulo, Brazil

Gaetano Santulli
Columbia University, New York, USA

Gianluigi Savarese
Karolinska Institutet, Stockholm, Sweden

Irina Savelieva
St George's University of London, London, UK

Udo Sechtem
Robert Bosch Krankenhaus, Stuttgart, Germany

Abhinav Sharma
McGill University, Montreal, Canada

Gerasimos Siasos
Brigham and Women's Hospital, Harvard Medical
School, Boston, USA

Tabassome Simon
Hôpitaux de Paris, Paris, France

Karen Sliwa-Hahnle
Hatter Institute for Cardiovascular Research in
Africa, University of Cape Town, South Africa

Philippe Gabriel Steg
Hôpital Bichat - Claude-Bernard, Paris, France

Ta-Chen Su, National Taiwan University
Hospital and National Taiwan University
College of Medicine

Christian Torp Pedersen
Aalborg University Hospital, Aalborg,
Denmark

Hung-Fat Tse
University of Hong Kong, Hong Kong

Wiek H van Gilst
University Medical Center Groningen, Groningen,
The Netherlands

Jeff Washam
Department of Medicine, Duke University

Sven Wassmann
Isarklinikum, Munich, Germany

Harvey White
Auckland City Hospital, Auckland, New Zealand

Petr Widimsky
Charles University, Prague, Czech Republic

José Luis Zamorano
University Hospital Ramón y Cajal, Seville, Spain

Faiez Zannad
Inserm-CHU, Nancy, France

European Heart Journal - Quality of Care & Clinical Outcomes

academic.oup.com/ehjqcco

EDITOR-IN-CHIEF

Adam Timmis
(Queen Mary University London,
United Kingdom)

DEPUTY EDITORS

Marcus Flather
(University of East Anglia, United Kingdom)
Chris Gale
(University of Leeds, United Kingdom)

Senior Consulting Editors

Harry Hemingway
(University College London, United
Kingdom)
Panos Vardas
(European Heart Health Institute, Belgium)
Paul Wilkinson
(London School of Hygiene & Tropical
Medicine, United Kingdom)

ASSOCIATE EDITORS

Fernando Alfonso
(Hospital Universitario de la Princesa,
Spain)
Andrew Archbold
(Barts Heart Centre, United Kingdom)
Andrew Clark
(University of Hull, United Kingdom)
Delphine de Smedt
(Ghent University, Belgium)
Harsh Golwala
(Oregon Health and Science University,
Portland, United States)
Eva Goossens
(University of Antwerp, Belgium)
Robert Henderson
(University of Nottingham, United
Kingdom)
Thao Huynh
(McGill University, Canada)
Charlotte Manisty (University College
London)
Heidi May
(Intermountain Medical Center Heart
Institute, United States)
Saidi Mohiddin
(Barts Heart Centre, United Kingdom)
Riyaz Patel
(University College London, United
Kingdom)
Muhammad Rashid
(Keele University, United Kingdom)
John Sanderson
(Capital Medical University, China)

STATISTICAL EDITORS

Alex McConnachie
(Glasgow University, United Kingdom)
Nicola Greenlaw
(Glasgow University, United Kingdom)
Caroline Haig
(Glasgow University, United Kingdom)
Rachel Zhang
(Glasgow University, United Kingdom)

REGIONAL ASSOCIATE EDITORS

Karen Alexander
(Duke University Medical Center, United States)
Maciej Banach
(Medical University of Lodz, Poland)
John Beltrame
(University of Adelaide, Australia)
Raffaele Bugiardini
(Department of Experimental, Diagnostic and
Specialty Medicine, University of Bologna, Italy)
Brian Griffin
(Cleveland Clinic, United States)
Tomas Jernburg
(Danderyd Hospital, Karolinska Institutet,
Sweden)
Rod Jackson
(University of Auckland, New Zealand)
Xi Li (Chinese Academy of Medical Sciences and
Peking Union Medical College, Beijing, China)
Elias Mossialos
(Department of Health Policy, London School of
Economics, United Kingdom)
Christopher Reid
(School of Public Health and Preventive Medi-
cine, Monash University, Australia)
Francois Schiele
(Regional University Hospital Jean Minjoz,
France)
Harriette Van Spall
(University of Toronto, Canada)
Andrew Yan
(University of Toronto, Canada)

SOCIAL MEDIA EDITOR

Diogo Ferreira
(Centro Hospitalar de Vila Nova de Gaia/
Espinho, Porto, Portugal)

EDITORIAL OFFICE

Jodie Elgey
(Oxford University Press, United Kingdom)
ehjqcco.editorialoffice@oup.com

European Heart Journal Supplements

The Heart of the Matter

EDITOR-IN-CHIEF

Roberto Ferrari
University of Ferrara, Italy & Maria Cecilia
Hospital, Italy

DEPUTY EDITORS

Jeroen Bax
Leiden University Medical Center, Netherlands
Michael Bohm
Saarland University, Germany
Francisco Fernández-Avilés
Hospital Clínico Universitario, Spain
Thomas F. Lüscher
University Hospital of Zürich, Switzerland
Frank Ruschitzka
University Hospital of Zürich, Switzerland

SENIOR CONSULTING EDITORS

Michel Bertrand
Institute Coeur Poumon, France
Claudio Rapezzi
University of Ferrara, Italy
Luigi Tavazzi
Maria Cecilia Hospital, Italy
Michał Tendera
Medical University of Silesia, Poland

STATISTICS EDITORS

Marco Manfrini
Maria Cecilia Hospital, Italy
Elisa Maietti
University of Bologna, Italy
Stefano Volpato
University of Ferrara, Italy

EDITORIAL OFFICE

E-mail: editor.ehjsheartofthematter@gmail.com

LOCAL ASSOCIATE EDITORS

Alberto Albertini
Maria Cecilia Hospital, Italy
Aneta Aleksova
University of Trieste, Italy
Pietro Ameri
IRCCS Ospedale Policlinico San Martino, Italy
Matteo Bertini
University of Ferrara, Italy
Gianluca Campo
University of Ferrara, Italy
Marco Canepa
University of Genoa and IRCCS Ospedale-
Policlinico San Martino, Genoa, Italy
Filippo Crea
Catholic University of the Sacred Heart, Italy
Alessandro Frigiola
IRCCS Policlinico San Donato, Italy, St
Thomas' Hospital, UK & King's College, UK
Alessandro Fucili
University of Ferrara, Italy

Francesco Giannini
Maria Cecilia Hospital, Italy
Aldo Pietro Maggioni
Cantù Hospital, European Society of Cardiology,
Fondazione ReS, Fondazione per il Tu cuore On-
lus, General Hospital "Fatebenefratelli", General
Hospital "G. Fornaroli", IRCCS Mario Negri
Institute, Liceo Classico Berchet, University of
Milan, University of Padova, Italy
Mario Marzilli
Università di Pisa, Italy
Donato Mele
University of Ferrara, Italy
Rita Pavasini
University of Ferrara, Italy
Paolo Sbarzaglia
Maria Cecilia Hospital, Italy

INTERNATIONAL EDITORIAL BOARD

Leonardo E. Abdo
Sanatorio Modelo S.A., Argentina
Stephan Achenbach
University of Erlangen-Nuremberg,
Germany
Ali A. AL-Awadhi
King Abdulaziz Cardiac Center, Kingdom of
Saudi Arabia
Hajar H.A. Al Binali
King Abdulaziz Cardiac Center, Kingdom of
Saudi Arabia
Erick Alexánder Rosas
Instituto Nacional de Cardiología "Ignacio
Chavez" & Universidad Nacional Au-
tonoma de Mexico, Mexico
Khalid Al Habib
King Abdulaziz Cardiac Center, Kingdom of
Saudi Arabia
Muayed Al Zaibag
King Abdulaziz Cardiac Center & King
Saud bin Abdulaziz University for Health
Sciences, Kingdom of Saudi Arabia

Stefan Anker
Berlin Institute of Health Center for Regenera-
tive Therapies, German Centre for Cardiovas-
cular Research & Charité Universitätsmedizin
Berlin, Germany
Eloisa Arbustini
Fondazione IRCCS Policlinico San Matteo, Italy
Dan Atar
Oslo University Hospital, Norway
Héctor Bueno
Hospital General Universitario Gregorio
Marañón, Spain
Oh Byung-Hee
Seoul National University Hospital, Korea
Yundai Chen
Chinese PLA General Hospital, China
Vijay K. Chopra
Max Super Speciality Hospital, India
Francesco Cosentino
Karolinska Institute & Karolinska University
Hospital, Sweden
Jamshed Dalal
Kokilaben Hospital, India

Nicolas Danchin
European Hospital Georges-Pompidou, France
Angelo Amato Vincenzo de Paola
Universidade Federal de São Paulo, Brazil
Niteen Deshpande
Spandan Heart Institute And Research Center,
India
Guillermo Fábregues
Fundación Favaloro, Argentina
Gerasimos Filippatos
Athens University Hospital Attikon, Greece
Junbo Ge
Shanghai Institute of Cardiovascular Disease &
Zhongshan Hospital Fudan University, China
Jorge Ilha Guimarães
Sociedade Brasileira de Cardiologia, Brazil
Gilbert Habib
La Timone Hospital, France
Yong Huo
Peking University First Hospital, China
Ng Wai Kiat
Pantai Hospital Kuala Lumpur Heart Centre,
Malaysia

INTERNATIONAL EDITORIAL BOARD

Michel Komajda
Pitié-Salpêtrière Hospital, University Pierre
and Marie Curie & IHU ICAN, France

Karl-Heinz Kuck
General Hospital St Georg, Germany
Glaucia Moraes de Oliveira
Federal University of Rio de Janeiro, Brazil

Ryozo Nagai
University of Tokyo Graduate School of
Medicine, Japan

Hani Najm
Cleveland Clinic, USA & King Fahad National
Guard Hospital, Kingdom of Saudi Arabia

Hisao Ogawa
National Cerebral and Cardiovascular Center,
Japan

Antonio Pelliccia
Institute of Sports Medicine and Science, Italy

Marco Antonio Peña-Duque
Instituto Nacional De Cardiologia, Brazil
Fausto Pinto

Centro Cardiovascular da Universidade de
Lisboa, Faculdade de Medicina, Universidade
de Lisbon and Serviço de Cardiologia & Hos-
pital Universitário de Santa Maria, Portugal

Piotr Ponikowski
Medical University Wroclaw, Poland

Francisco Javier Roldán
Instituto Nacional de Cardiología, Mexico

Mohd Ali Rosli
Cardiac Vascular Sentral, Malaysia

Abhishek Sharma
Gundersen Health System, Wisconsin, USA

Hiroaki Shimokawa
Tohoku University Graduate School of
Medicine, Japan

Karen Sipido
KU Leuven, Belgium

Carlos Tajer
Hospital de Alta Complejidad El Cruce, Argentina

Panos Vardas
Hygeia Hospitals Group, Greece

Stephan Windecker
Université Pierre et Marie Curie, France & Bern
University Hospital, Switzerland

Salim Yusuf
McMaster University & Hamilton General Hospital,
Canada

Mohammad Zubaid
Kuwait University & Mubarak Al Kabeer Hospital,
Kuwait

Copyright Notice and Disclaimer

This Excerpts Edition is compiled and published by Passi HealthCom and consists of a collection of articles selected by Passi HealthCom from academic and/or research journals originally published in the English language by Oxford University Press. Passi HealthCom has obtained permission to publish this Excerpts Edition and to distribute it to medical professionals within India.

EHJ - Cardiovascular Pharmacotherapy © European Society of Cardiology 2022

EHJ - Quality of Care and Clinical Outcomes © European Society of Cardiology 2022

EHJ - Supplements © European Society of Cardiology 2022

EHJ - Case Reports © European Society of Cardiology 2022

Cardiovascular Research © European Society of Cardiology 2022

All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of Oxford University Press and/or Oxford Publishing Limited ("OPL") or as expressly permitted by law.

The mention of trade names, commercial products or organizations, and the inclusion of advertisements in the Excerpts Edition does not imply a guarantee or endorsement of any kind by Oxford University Press, OPL, or any of their licensors.

All reasonable precautions were taken by Oxford University Press and the original editors to verify drug names and doses, the results of experimental work and clinical findings published in the Journal. The ultimate responsibility for the use and dosage of drugs mentioned in the Journal and reproduced in this Excerpts Edition, and in interpretation of published material, lies with the medical practitioner. Oxford University Press, OPL nor any of their licensors accept any liability whatsoever in respect of any claim for damages or otherwise arising therefrom. Please inform Passi HealthCom of any errors.

The opinions expressed in the Journal articles reproduced in this Excerpts Edition are those of the original authors and do not necessarily reflect those of Oxford University Press, OPL or any of their licensors.

The use of registered names, trademarks etc. in this Excerpts Edition does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore free for general use.

ESC Spotlight

CONTENTS

12

Optimizing individual heart failure treatment

European Heart Journal - Cardiovascular Pharmacotherapy (2022) 0, 1–3
<https://doi.org/10.1093/ehjcvp/pvab087>

15

ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2

European Heart Journal - Cardiovascular Pharmacotherapy (2022) 0, 1–11
<https://doi.org/10.1093/ehjcvp/pvac021>

26

Updates from the American Heart Association Scientific Sessions: cardiovascular pharmacotherapy

European Heart Journal - Cardiovascular Pharmacotherapy (2022) 8, 313–315
<https://doi.org/10.1093/ehjcvp/pvab084>

29

Management of antithrombotic therapy in patients at high bleeding risk after percutaneous coronary intervention for acute coronary syndromes: a case report

European Heart Journal - Case Reports (2022) 6, 1–6
<https://doi.org/10.1093/ehjcr/ytac224>

Journals Subscription
Department
Oxford University Press
Great Clarendon Street
Oxford, OX2 6DP, UK
Tel: +44 (0)1865 353907
Fax: +44 (0)1865 353485

Optimizing individual heart failure treatment

Stefan Agewall *

Oslo University Hospital Ullevål and Institute of Clinical Sciences, University of Oslo, Oslo, Norway



A mineralocorticoid receptor antagonist (MRA) is recommended in patients with chronic heart failure.^{1–5} However, the effects of the early initiation of an MRA in patients with acute heart failure (AHF) is less documented. Kitakaze and co-workers from Japan have performed a multicentre, randomized, double-blind, placebo-controlled, parallel-group study in 300 patients with AHF. The patients were randomized to eplerenone or placebo. The primary outcome was a composite of cardiac death or first rehospitalization due to cardiovascular disease within 6 months. No significant difference in primary outcome was found. The authors concluded that early initiation of eplerenone in patients with AHF could safely be utilized.

The PARADIGM-HF study⁶ did not analyse the effect of ventricular remodelling on patients with different aetiologies, which may affect clinical treatment outcomes. In a paper from Taiwan, Chang and co-workers aimed to compare left ventricular ejection fraction (LVEF) following sacubitril/valsartan (SAC/VAL) treatment and its association with clinical outcomes in 1576 patients. The authors found that patients with non-ischaeamic cardiomyopathy (NICM) had a higher degree of LVEF improvement than those with ischaemic cardiomyopathy (ICM) following SAC/VAL treatment, and significant improvement of LVEF in NICM patients.

Anticancer drugs may be associated with different kinds of heart problems.^{7–9} The anti-HER2 agent trastuzumab reduces risk of disease progression or death in breast cancer patients.⁹ However, HER2 isoforms are also expressed in cardiomyocytes and may cause increased risk of left ventricular (LV) dysfunction and a five- to seven-fold increased risk of heart failure.⁹ Paterson and co-workers from Canada aimed to characterize the cardiac and cardiometabolic phenotype of trastuzumab-mediated toxicity and potential interactions with cardiac pharmacotherapy. The study was an analysis of serial magnetic resonance imaging (MRI) and circulating biomarker data acquired from patients with HER2-positive early stage breast cancer participating in a randomized controlled clinical trial for the pharmacoprevention of trastuzumab-associated cardiotoxicity. The authors report that trastuzumab results in impaired cardiac function and early myocardial inflammation. Trastuzumab was also associated with deleterious changes to the cardiometabolic phenotype,

which may contribute to the increased cardiovascular risk in this population.

The beneficial effect of β -blocker on heart failure with reduced ejection fraction (HFrEF) is well established.^{1,10} However, its effect on the short-term outcome of heart failure with midrange ejection fraction (HFmrEF) is less clear. Zheng *et al.* from China have analysed the data of 1036 patients with LVEF between 40% and 49% in China The Patient-centred Evaluative Assessment of Cardiac Events Prospective Heart Failure (China, PEACE 5p-HF) study. Two primary outcomes were all-cause death and all-cause hospitalization. The authors concluded that in patients with HFmrEF, β -blocker use was associated with lower risk of all-cause death, but not with lower risk of all-cause hospitalization.

Uncontrolled blood pressure (BP) increases the risk of developing HF.¹ The effect of spironolactone on the BP of patients at risk of developing HF is yet to be determined. Ferreira and co-workers aimed to evaluate the effect of spironolactone on the BP of patients at risk for HF and whether renin can predict spironolactone's effect in a prospective multicentre randomized open-label blinded endpoint (PROBE) trial including 527 patients at risk for developing HF randomly assigned to either spironolactone (25–50 mg/day) or usual care alone for a maximum of 9 months. The authors report that a higher proportion of patients on spironolactone had controlled BP in the spironolactone group and lower baseline renin levels predicted a greater response to spironolactone. The conclusion of the study was that spironolactone should be considered for lowering blood pressure in patients who are at risk of developing HF.

The pandemic caused by the SARS-CoV-2 virus has spread worldwide and many questions about the pathophysiology of the SARS-CoV-2 infection are unanswered. In a study from Spain, Masana and co-workers aimed at assessing the effect of statin therapy at hospital admission for COVID-19 on in-hospital mortality. In a retrospective observational study, they report a significantly lower mortality rate in patients on statin therapy than the matched non-statin group and the mortality rate was even lower in patients who maintained their statin treatments during hospitalization compared with the non-statin group. Also, the Cox model suggested that statins were associated with reduced COVID-19-related mortality. The authors

* Email: stefan.agewall@medisin.uio.no

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

concluded that a lower SARS-CoV-2 infection-related mortality was observed in patients treated with statin therapy prior to hospitalization. Statin therapy should not be discontinued due to the global concern of the pandemic or in patients hospitalized for COVID-19. Several other observational studies have shown potential beneficial effects of lipid-lowering treatment on the course of COVID-19 with significantly improved prognosis and reduced mortality.^{11–13} Findings from ongoing rigorously conducted and adequately powered randomized clinical trials (RCTs) can assess the possible efficacy of lipid-modulating agents in the prevention or treatment of various stages of COVID-19 and may open new horizons for research and clinical practice.¹⁴

Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEis/ARBs) is thought to affect COVID-19 through modulating levels of angiotensin-converting enzyme 2, the cell entry receptor for SARS-CoV2.^{15,16} There are many observational studies on this topic.^{17,18} In a meta-analysis, McMurray and co-workers included non-randomized observational COVID-19 studies, comparing ACE inhibitor/ARB treatment. Eighty six studies, including 459 755 patients (103 317 with hypertension), were analysed. In patients with hypertension, ACE inhibitor or ARB treatment was not associated with a greater likelihood of SARS-CoV-2 infection in 60 141 patients, hospitalization or case fatality in 18 735 patients with 2893 deaths. In all patients (irrespective of hypertension), findings were consistent for likelihood of SARS-CoV-2 infection in 363 865 patients. The authors concluded that ACE inhibitors and ARBs appear safe in the context of SARS-CoV-2 infection and should not be discontinued.

The rising prevalence of obesity and its associated comorbidities represents a growing public health issue, as a risk factor for both cardiovascular disease^{19,20} and COVID-19. Many randomized controlled trials have demonstrated the clinical utility of orlistat in achieving weight loss when compared with lifestyle measures alone.^{21–23} Collins and co-workers aimed to explore long-term cardiovascular outcomes after orlistat therapy in a propensity score matched cohort study of healthcare records of the Clinical Practice Research Datalink. The 36 876 patients with obesity who had completed a course of orlistat were matched with controls who had not taken orlistat. The authors concluded that orlistat was associated with lower rates of overall major adverse cardiovascular events, new onset heart failure, renal failure, and mortality during the median study follow-up of 6 years.

Heart failure patients are usually at high risk of polypharmacy and, consequently, potentially inappropriate prescribing leading to poor clinical outcomes.^{24–26} We are pleased to publish a position statement from Coats and co-workers entitled 'Position statement on HFrEF specific inappropriate prescribing'.

References

- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibellund AK, ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2021;**42**:3599–3726.

- Savarese G, Lund LH, Rosano GMC, Coats AJ. New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress. *Eur Heart J Cardiovasc Pharmacother* 2021;**7**:e89–e90.
- Becher PM, Savarese G. PharmaPulse: new trial evidence from the HFA/ESC Heart Failure Congress 2021. *Eur Heart J Cardiovasc Pharmacother* 2021;**7**:e88.
- Ameri P, Bertero E, Maack C, Teerlink JR, Rosano G, Metra M. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment? *Eur Heart J Cardiovasc Pharmacother* 2021;**7**:539–546.
- Simpson J, Jackson CE, Haig C, Jhund PS, Tomaszewski M, Gardner RS, Tsorlalis Y, Petrie MC, McMurray JJV, Squire IB, Gupta P. Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography-tandem mass spectrometry-based urine analysis. *Eur Heart J Cardiovasc Pharmacother* 2021;**7**:296–301.
- McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014;**371**:993–1004.
- Alexandre J, Salem JE, Moslehi J, Sassi M, Ropert C, Cautela J, Thuny F, Ederhy S, Cohen A, Damaj G, Vilque JP, Plane AF, Legallois D, Champ-Rigot L, Milliez P, Funck-Brentano C, Dolladille C. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. *Eur Heart J Cardiovasc Pharmacother* 2021;**7**:312–320.
- Keramida K, Filippatos G, Farmakis D. Cancer treatment and atrial fibrillation: use of pharmacovigilance databases to detect cardiotoxicity. *Eur Heart J Cardiovasc Pharmacother* 2021;**7**:321–323.
- Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. *Oncologist* 2008;**13**:620–630.
- Joo SJ, Kim SY, Choi JH, Park HK, Beom JW, Lee JG, Chae SC, Kim HS, Kim YJ, Cho MC, Kim CJ, Rha SW, Yoon J, Jeong MH. Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction. *Eur Heart J Cardiovasc Pharmacother* 2021;**7**:475–482.
- Bifulco M, Gazzerro P. Statin therapy in COVID-19 infection: much more than a single pathway. *Eur Heart J Cardiovasc Pharmacother* 2020;**6**:410–411.
- Abdel-Latif RG, Mohammed S, Elgendy IY. Statin therapy and SAR-COV-2: an available and potential therapy? *Eur Heart J Cardiovasc Pharmacother* 2020;**6**:333–334.
- Castiglione V, Chiriacò M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. *Eur Heart J Cardiovasc Pharmacother* 2020;**6**:258–259.
- Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannnejad H, Gupta A, Madhavan MV, Van Tassel BW, Jimenez D, Monreal M, Vaduganathan M, Fanikos J, Dixon DL, Piazza G, Parikh SA, Bhatt DL, Lip GYH, Stone GW, Krumholz HM, Libby P, Goldhaber SZ, Bickdeli B. Investigating lipid-modulating agents for prevention or treatment of COVID-19: JACC State-of-the-Art Review. *J Am Coll Cardiol* 2021;**78**:1635–1654.
- Lu R, Zhao X, Li J, Niu P, Yang BO, Wu H, Wang W, Song H, Huang B, Zhu NA, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020;**395**:565–574.
- Offringa A, Montijn R, Singh S, Paul M, Pinto YM, Pinto-Sietsma SJ. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system. *Eur Heart J Cardiovasc Pharmacother* 2020;**6**:317–325.
- Dalan R, Ang LW, Tan WYT, Fong SW, Tay WC, Chan YH, Renia L, Ng LFP, Lye DC, Chew DEK, Young BE. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. *Eur Heart J Cardiovasc Pharmacother* 2021;**7**:e48–e51.
- Cannata F, Chiarito M, Reimers B, Azzolini E, Ferrante G, My I, Viggiani G, Panico C, Regazzoli D, Ciccarelli M, Voza A, Aghemo A, Li H, Wang Y, Condorelli G, Stefanini GG. Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. *Eur Heart J Cardiovasc Pharmacother* 2020;**6**:412–414.
- Javed S, Gupta D, Lip GYH. Obesity and atrial fibrillation: making inroads through fat. *Eur Heart J Cardiovasc Pharmacother* 2021;**7**:59–67.
- Napoli C, Benincasa G, Schiano C, Salvatore M. Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients. *Eur Heart J Cardiovasc Pharmacother* 2020;**6**:239–247.
- Lindgärde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. *J Intern Med* 2000;**248**:245–254.

22. Zhou YH, Ma XQ, Wu C, Lu J, Zhang SS, Guo J, Wu SQ, Ye XF, Xu JF, He J. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. *PLoS One* 2012;**7**:e39062.
23. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. *BMJ* 2007;**335**:1194–1199.
24. Kaski JC, Tamargo J, Savarese G. Cardiovascular pharmacotherapy in older people: challenges posed by cardiovascular drug prescription in the elderly. *Eur Heart J Cardiovasc Pharmacother* 2020;**6**:277–279.
25. Lip GYH, Keshishian A, Kang A, Dhamane AD, Luo X, Klem C, Rosenblatt L, Mardekian J, Jiang J, Yuce H, Deitelzweig S. Effectiveness and safety of oral anti-coagulants among non-valvular atrial fibrillation patients with polypharmacy. *Eur Heart J Cardiovasc Pharmacother* 2021;**7**:405–414.
26. Vanassche T, Verhamme P, Anand SS, Shestakovska O, Leong DP, Fox KAA, Bhatt DL, Avezum A, Alings M, Aboyans V, Maggioni AP, Widimsky P, Muehlhofer E, Berkowitz SD, Yusuf S, Connolly SJ, Eikelboom JW, Bosch J. Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multi-morbidity: an analysis from the COMPASS trial. *Eur Heart J Cardiovasc Pharmacother* 2021; doi: 10.1093/ehjcvp/pvab050. Published online ahead of print 30 June 2021.

ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2

David Sulman[†], Michel Zeitouni[†], Johanne Silvain, Mathieu Kerneis, Paul Guedeney, Olivier Barthélémy, Delphine Brugier, Pierre Sabouret, Benoit Lattuca, Emilie Mertens, Julianne Posson, Niki Procopi, Tomy Salloum, Jean-Philippe Collet  and Gilles Montalescot 

ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Sorbonne Université, 83 boulevard de l'hôpital, 75013, Paris, France

Received 3 February 2022; revised 3 March 2022; accepted 23 March 2022; online publish-ahead-of-print 5 April 2022

Aims

The European Society of Cardiology (ESC) has released three consecutive guidelines within 5 years addressing cardiovascular prevention, risk scores, and cholesterol treatment. This study aims to evaluate whether the 2021 ESC guidelines improved the eligibility of individuals for primary prevention statin therapy before their first ST-segment elevation myocardial infarction (STEMI), and for intensive lipid-lowering treatments in secondary prevention.

Methods and results

The cardiovascular risk category of 2757 consecutive individuals admitted for a first STEMI was evaluated to assess whether they would have been eligible for primary prevention statins according to 2021 vs. 2019 and 2016 ESC guidelines. Eligibility for intensive lipid-lowering therapy in secondary prevention was assessed according to the real-life follow-up low-density lipoprotein cholesterol (LDL-C) and the expected follow-up LDL-C. More individuals would have been eligible for primary prevention statins according to 2021 and 2019 vs. 2016 guidelines (61.8% vs. 38.7% vs. 23.6%, $P < 0.01$), a finding observed in both men (62.3% vs. 35.0% vs. 24.9%, $P < 0.01$) and women (60.2% vs. 50.7% vs. 19.3%, $P = 0.18$). Only 27% of individuals reached the LDL-C objective of 55 mg/L in secondary prevention: using the ESC stepwise approach, 61.7% were eligible for higher doses of statins, 26.2% for ezetimibe, and 12.1% for a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (PCSK9i). Based on expected LDL-C reductions, eligibility for a PCSK9i in secondary prevention was greater with 2021 vs. 2016 guidelines (44.5% vs. 22.5%, $P < 0.01$).

Conclusion


The 2021 ESC guidelines improved the detection and treatment of individuals at risk for a first myocardial infarction. In secondary prevention, 70% of patients kept LDL-C levels above 55 mg/dL: increasing the statin dose and adding ezetimibe were the most frequently recommended therapeutic actions.

* Corresponding author. Tel: 01 42 16 30 07, Fax: 01 42 16 29 23, Email: gilles.montalescot@aphp.fr

[†] The first two authors contributed equally to this manuscript.

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Graphical Abstract



Keywords

Cardiovascular risk • Dyslipidaemia • Statin • PCSK9 inhibitor

Introduction

Despite the major advancements in the detection and treatment of cardiovascular risk, cardiovascular disease (CVD) is still the main cause of mortality in Europe with 4 million deaths per year, including 2.2 million deaths of women.^{1,2} From 2016 to 2021, the European Society of Cardiology (ESC) provided three consecutive guidelines aiming to prevent cardiovascular disease.^{3–5} In 2019, the *ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk* updated the recommendations on the detection and treatment of individuals at risk in primary and secondary prevention with the following major changes: first, the task force implemented risk modifiers to target specific populations at risk, especially sex-related risk factors, in the algorithms; secondly, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are recommended with a class I for very high risk patients before any symptomatic cardiovascular disease; thirdly, in secondary prevention, PCSK9is are recommended on top of statins and ezetimibe in case of a persistently elevated low-density lipoprotein cholesterol (LDL-C) above 55 mg/dL (1.4 mmol/L). In 2021, the *ESC Guidelines on Cardiovascular Disease (CVD) Prevention in Clinical Practice* (2021 ESC guidelines) implemented the use of Systematic Coronary Risk Estimation 2 (SCORE2) and Systematic Coronary Risk Estimation 2—Older Persons (SCORE2-OP) in place of the Systematic Coronary Risk Estimation (SCORE), which was reported to underestimate the CVD burden because of including only fatal events.^{6–8} Population-based studies have demonstrated the limitations of previous ESC guidelines to detect and recommend primary prevention statins in patients at risk of cardiovascular disease. Furthermore, while theoretical estimations of ezetimibe and PCSK9i eligibility in secondary prevention have been based on LDL-C expected reductions, the real-life effect of the stepwise approach in patients after a first ST-segment elevation myocardial infarction (STEMI) is unknown.

Thus, using baseline characteristics of patients admitted for a first STEMI, our primary objective was to assess whether they would have been eligible for primary prevention statins based on 2021, 2019, and 2016 ESC guidelines if they had been seen before this first event. Our second objective was to evaluate the guideline-recommended response for intensive lipid-lowering therapies in secondary prevention overall and according to sex.

Methods

Study design and population

The e-PARIS registry is a prospective registry of all consecutive individuals admitted for an STEMI at the University Hospital of Pitié-Salpêtrière, Paris, France. The design of the e-PARIS registry has been well described before.^{9,10} In brief, it includes a pre-specified data set of clinical and biological characteristics, cardiovascular risk factors, angiographic characteristics, and follow-up for major non-fatal cardiovascular events and vital status. For the present study, we included individuals of the e-PARIS registry admitted for a first STEMI between January 2000 and October 2018, free of prior cardiovascular disease, with available cholesterol samples at admission. STEMI was defined as the presence of clinical myocardial ischaemia, associated with new or presumed new ST-segment elevation of 1 mm or more in two or more contiguous leads, bundle-branch block, or true posterior myocardial infarction (MI). The final diagnosis of STEMI was confirmed by the presence of an acute coronary artery occlusion during the coronary angiography. The registry was approved by the local ethical committee of the University Hospital Pitié-Salpêtrière of Paris.

Cardiovascular risk assessment prior to first ST-segment elevation myocardial infarction

Cardiovascular risk prior to first STEMI was estimated using the data collected at admission. The ESC/ European Atherosclerosis Society (EAS)

guidelines classify individuals as 'very high risk', 'high risk', 'moderate risk', and 'low risk', with each category related to goals of LDL-C levels to determine eligibility for primary prevention statins. Following 2019 and 2021 ESC/EAS algorithms (Supplementary material online, *Tables S1 and S2*), individuals were classified based on (1) prior high-risk comorbidities such as diabetes with or without target organ damage, severe or moderate chronic kidney disease, familial hypercholesterolaemia, and severe arterial hypertension; (2) the SCORE (2016 and 2019 ESC guidelines) and SCORE2 (2021 ESC guidelines) charts for low-risk countries for 'apparently healthy individuals' (without previous high-risk comorbidities); and (3) their baseline LDL-C at admission. This risk estimation allowed assessing the number of individuals who would have been recommended for preventive statin treatment before their first STEMI.

Interpretation of 2019 and 2021 ESC guidelines for primary prevention

The updates that occurred from the 2016 to 2019/2021 ESC guidelines are reported in the Supplementary material online, *Table S3*. In brief, the 2019 ESC/EAS guidelines provided several updates compared with the 2016 ESC/EAS guidelines: first, the SCORE model included patients up to 70 years of age, compared with 65 years in prior guidelines; secondly, individuals aged 70 or more were considered eligible for statins (class IIb), while there was no prior recommendation for this age category before; more importantly, low-risk and moderate-risk individuals became eligible for direct intervention with statins in case of LDL-C above the level of 190 mg/dL. The recommendation for primary prevention using statins was updated from class IIa to I for all the high-risk individuals with a baseline LDL-C above 100 mg/dL. PCSK9i therapy was recommended for individuals at very high risk and uncontrolled LDL-C under maximal tolerated dose of statins and ezetimibe, either in a primary prevention setting (class IIb) or in secondary prevention (class I).

In the 2021 ESC guidelines, SCORE was replaced by SCORE2/ZOP to stratify the risk of individuals without diabetes and without prior cardiovascular disease. The newness of SCORE2/ZOP is that it included individuals from 40 to 89 years old, provides a different risk stratification giving more importance for risk factors other than for age or sex, and evaluates the risk of both non-fatal and fatal events at 10 years. The age extension allows a better risk screening, especially in female individuals who present their coronary events later than male ones.¹¹ The model was validated using a global population of 12.5 million individuals. Patients already treated with statins at admission were considered as eligible for both guidelines.

Eligibility for intensive lipid-lowering therapy after a first ST-segment elevation myocardial infarction

In secondary prevention, real-life follow-up LDL-C and guideline-based response were also evaluated among a subset of patients with intrahospital follow-up by using consultation reports and hospitalizations records. Medical data were checked for LDL-C levels until a censoring point of death occurrence or the date of 1 January 2021. Persistent active smoking, hypertension (>140/90 mmHg), diabetes control (Hb1ac > 6.5%), and lipid-lowering therapies prescribed were also obtained. Eligibility was assessed using the collected data and each patient's specific follow-up.

In a secondary analysis, the individual LDL-C level expected during follow-up was calculated based on baseline LDL-C, following the ESC guidelines: 50% of baseline LDL-C reduction in individuals discharged with high-intensity statins, 65% of baseline LDL-C reduction in individuals discharged with high-intensity statins plus ezetimibe, and 85% reduction

of baseline LDL-C with high-intensity statins with ezetimibe plus PCSK9i. Thus, using the expected LDL-C follow-up and considering a maximal dosage of statin at discharge with full adherence, we also tried to assess the theoretical eligibility for either ezetimibe or PCSK9i.

Similarly, major adverse cardiovascular events (MACEs) defined by death, recurrence of acute coronary syndrome (ACS), or stroke were collected.

Endpoints

The first objective was to compare the 2016, 2019, and 2021 ESC/EAS guidelines' efficiency to detect and treat patients who will develop a first STEMI, and then in men vs. women. Thus, eligibility for statins prior to a first STEMI was defined as a class I, IIa, or IIb recommendation. Secondly, we compared the proportion of men and women with hospital follow-up eligible for an intensive lipid-lowering therapy with PCSK9i and ezetimibe, based on real-life LDL-C. A similar analysis was performed according to expected reductions of LDL-C as described in ESC/EAS guidelines.

Statistical analysis

Continuous variables are presented as median and interquartile ranges and compared across sex categories using *P*-values for trends: Cochran–Armitage Trend test for binary variables, Cochran–Mantel–Haenszel test for categorical variables, and Spearman correlation test for continuous variables. Descriptive summaries of the cohort and risk factors are based on available data with missing values excluded from calculations. The performance of the 2016 and 2021/2019 ESC/EAS guidelines were compared using a Welch/Student's *t*-test or the Mann–Whitney *U* test, as appropriate. No adjustment was made for multiple comparisons. A two-sided *P*-value <0.05 was considered significant. Statistical analysis was performed using GraphPad Prism version 6.04 for Windows, GraphPad Software, La Jolla, CA, USA.

Results

Baseline characteristics

Between February 2000 and October 2018, 2757 patients were admitted for a first STEMI, including 648 women (23.5%). Baseline characteristics are displayed in *Table 1*. Risk modifiers were more frequent in women than men, especially chronic inflammatory diseases. The median LDL-C level at admission for acute MI was 115 mg/dL (2.9 mmol/L) in women [interquartile range (IQR) 92–151] and 121 mg/dL (3.1 mmol/L) in men (IQR 92–151) (*P* = 0.52).

According to 2019 ESC guidelines, 17.2% of individuals with a first STEMI would have been considered at very high risk for a MACE (*Table 2*). Following the updates provided by the 2021 ESC/EAS guidelines, using SCORE2, 40.9% of individuals were considered at very high risk for a first major cardiovascular (*Table 2*). The SCORE and SCORE2 of individuals aged at least 40 years old without diabetes or chronic kidney disease are displayed in the Supplementary material online, *Table S4*.

At discharge, the maximal dosage of statin was administered to 72.4% of patients, with women being less likely to be discharged on the maximal dose of statin (69.8% vs. 73.1%, *P* < 0.001). Atorvastatin was the most prescribed drug.

Table 1 Baseline characteristics according to sex

	Overall, <i>n</i> = 2757	Men, <i>n</i> = 2109	Women, <i>n</i> = 648	<i>P</i> -value
Age	56.8 (45.8–68.94)	54.5 (44.9–64.7)	67.3 (54.1–81.1)	<0.001
BMI	20.6 (16.9–25.4)	25.5 (23.7–28.4)	24.4 (21.7–27.7)	<0.001
Obese (BMI >30 kg/m ²)	346/2443 (14.1%)	255/1877 (13.6%)	90/566 (15.9%)	
Smoking status				
Never	947 (34.4%)	581 (27.6%)	366 (56.5%)	<0.001
Active	1395 (50.6%)	1192 (56.5%)	203 (31.2%)	—
Prior	415 (15.0%)	336 (15.9%)	79 (12.1%)	—
Familial history of CAD	735 (26.6%)	565 (27.8%)	170 (26.2%)	0.78
Hypertension	1066 (38.7%)	720 (34.1%)	346 (53.4%)	<0.001
Diabetes	518 (18.8%)	390 (18.5%)	128 (19.7%)	0.47
GFR < 30 mL/min/1.73 m ²	79 (2.9%)	32 (1.5%)	47 (7.2%)	<0.001
GFR median (mL/min/1.73 m ²)	95.3 (67.11–122.1)	102 (78.5–126.3)	67 (45.6–94.14)	<0.001
Risk modifiers				
At least one risk modifier	859/2567 (33.4%)	656/2031 (32.3%)	203/536 (37.9%)	0.015
Atrial fibrillation	104 (4.0%)	73 (3.6%)	31 (5.8%)	0.022
Chronic immune-mediated inflammatory disorder	67 (2.6%)	45 (2.2%)	22 (4.1%)	0.015
CKD	145 (5.6%)	108 (5.3%)	37 (6.9%)	0.16
HIV	50 (1.9%)	46 (2.3%)	4 (0.7%)	0.024
LV hypertrophy	213 (8.3%)	167 (8.2%)	47 (8.7%)	0.69
NASH	14 (0.5%)	11 (0.5%)	3 (0.5%)	1
Obstructive sleep syndrome	49 (1.9%)	44 (2.2%)	5 (0.8%)	0.063
Physical inactivity	165 (6.4%)	127 (6.3%)	38 (7%)	0.48
Psychiatric disorder	170 (6.6%)	112 (5.5%)	58 (10.8%)	<0.001
Social deprivation	235 (9.1%)	187 (9.2%)	48 (8.9%)	0.85
Localization of MI				
Anterior	1609 (58.4%)	1250 (59.3%)	359 (55.4%)	
Lateral	209 (7.6%)	159 (7.5%)	50 (7.7%)	
Inferior	921 (33.4%)	688 (32.6%)	233 (35.9%)	
Other	18 (0.6%)	12 (0.6%)	6 (0.9%)	
Angiographic findings				
Single-vessel disease	1759 (63.8%)	1340 (63.5%)	419 (64.7%)	0.45
Two-vessel disease	577 (20.9%)	437 (20.7%)	140 (21.6%)	—
Three-vessel disease	421 (15.3%)	332 (15.7%)	89 (13.7%)	—
Lipid data				
Statins prior to admission	266 (9.6%)	216 (10.2%)	50 (7.7%)	0.44
LDL-C > 190 mg/dL	233 (8.4%)	177 (8.3%)	53 (8.2%)	0.84
LDL-C > 160 mg/dL	503 (18.2%)	386 (18.3%)	117 (18.0%)	0.89
LDL-C (mg/dL)	120 (90–151)	121 (92–151)	115 (87–150)	0.52
HDL-C (mg/dL)	43 (34–53)	40 (33–50)	51 (41–63)	<0.001
Total cholesterol (mg/dL)	192 (165–224)	192 (164–221)	195 (165–233)	<0.01
Triglycerides (mg/dL)	120 (87–166)	122 (90–174)	109 (82–150)	<0.001
Other biological data				
Creatinine (μmol/L)	75 (63–89)	77 (66–90)	66 (54–83)	<0.001
Troponin (mg/L)	139 (18.6–3150)	133 (19.8–3111)	150 (13.0–3414)	0.11
NtproBNP (pg/mL)	1015 (250–3146)	806 (220–2504)	2182 (434–4702)	<0.001
Haemoglobin (g/dL)	12.9 (11.6–13.9)	13.2 (12.1–14.1)	11.6 (10.5–12.6)	<0.001
Hb1aC (%)	5.80 (5.50–6.30)	5.80 (5.50–6.30)	5.90 (5.57–6.30)	0.32
CRP _{us} (mg/L)	6.00 (2.00–24.0)	6.00 (2.00–22.0)	7.00 (2.00–31.0)	0.16
Type and dosage of statin at discharge				
Every statin at maximum dosage, <i>n</i> (%)	1338/1849 (72.4%)	1058/1448 (73.1%)	280/401 (69.8%)	<0.001
Atorvastatine 80 mg, <i>n</i> (%)	1152 (62.3%)	941 (64.9%)	211 (52.6%)	<0.001
Atorvastatine 40 mg or less, <i>n</i> (%)	288 (15.6%)	185 (12.8%)	104 (25.9%)	—
Rosuvastatine 20 mg, <i>n</i> (%)	154 (8.3%)	134 (9.3%)	20 (5.0%)	—
Rosuvastatine 10 mg or less, <i>n</i> (%)	116 (6.3%)	90 (6.2%)	26 (6.5%)	—
Others	80 (4.3%)	56 (3.9%)	24 (6.0%)	—
None	59 (3.2%)	43 (2.9%)	16 (4.0%)	—

BMI, body mass index; CAD, coronary artery disease; GFR, glomerular filtration rate; CKD, chronic kidney disease; HIV, human immunodeficiency virus; LV, left ventricle; NASH, non-alcoholic steatohepatitis.

Table 2 Estimation of cardiovascular risk in primary prevention according to sex

	Overall, n = 2757	Men, n = 2109	Women, n = 648	P-value
Risk category—ESC 2019 ^a				
Low risk	449 (16.3%)	374 (17.7%)	75 (11.6%)	<0.001
Moderate risk	1033 (37.5%)	855 (40.5%)	178 (27.5%)	—
High risk	692 (25.1%)	444 (21.1%)	248 (38.3%)	—
Very high risk	474 (17.2%)	368 (17.4%)	106 (16.4%)	—
Risk category—ESC 2021 ^b				
Low to moderate risk	539 (19.6%)	404 (19.2%)	135 (20.8%)	0.33
High risk	1088 (39.5%)	826 (39.2%)	262 (40.4%)	—
Very high risk	1130 (40.9%)	879 (41.6%)	251 (38.8%)	—
Eligibility for statins (grade I, IIa, IIb)				
2016 ESC guidelines	650 (23.6%)	525 (24.9%)	125 (19.3%)	<0.001
2019 ESC guidelines	1066 (38.7%)	738 (35.0%)	328 (50.6%)	<0.001
2021 ESC guidelines	1704 (61.8%)	1314 (62.3%)	390 (60.2%)	0.18

^aBased on clinical factors and SCORE.^bBased on clinical factors and SCORE2.

Eligibility for primary prevention intervention in men and women

Based on the 2021 ESC guidelines, 61.8% of individuals would have met a class I, IIa, or IIb recommendation for primary prevention statins prior to STEMI, 38.6% according to the 2019 ESC/EAS guidelines, and 24% with the 2016 guidelines ($P < 0.01$) (Figure 1A). The increase in detection of individuals at risk from 2016 to 2021 occurred in both women (60.2% vs. 50.7% vs. 19.3%, $P < 0.001$) and men (62.3% vs. 35.0% vs. 24.9%, $P < 0.001$) (Figure 1B). Of note, based on the 2016 ESC guidelines, 24% of patients were not given any recommendation—either because of too low CV risk or because of their age being too advanced. The proportion of patients left out of any recommendation dropped to 5% with the 2019 guidelines, and 0% in 2021.

According to the 2019 ESC/EAS guidelines, 368 (17.4%) men and 106 (16.4%) women were considered at very high risk and thus would be potentially eligible for primary prevention PCSK9i in case of uncontrolled LDL-C with statins and ezetimibe. According to the 2021 ESC guidelines, intensive lipid-lowering therapy before a first cardiovascular event in very high risk patients would involve 879 (41.6%) men and 251 (38.8%) women.

Guideline-based intensive lipid-lowering therapy after a first ST-segment elevation myocardial infarction according to real-life low-density lipoprotein cholesterol (n = 975 patients)

Using health records linked to the ePARIS registry, the LDL-C levels of 975 patients were collected. After a median follow-up of 33 months [interquartile range: 7–71] after the MI, only 27% of patients reached the LDL-C objective below 55 mg/dL (1.4 mmol/L), and 39% below 70 mg/dL (1.8 mmol/L) (Figure 2).

Following the stepwise approach recommended by ESC guidelines, among 711 patients out of the LDL-C objective during follow-up, 439 (61.7%) were eligible for an increase of their statin dosage, 186 (26.2%) were eligible to add ezetimibe, and 86 (12.1%) were eligible to add a PCSK9i because they were already on the maximally tolerated dose of statins and ezetimibe without significant gender differences (Figure 3A and B). Following its introduction in the 2021 ESC guidelines with a class IIb recommendation, 189 (19.4%) patients were also eligible to add icosapent ethyl due to a triglyceride level >135 mg/dL.

Guideline-based intensive lipid-lowering therapy after a first ST-segment elevation myocardial infarction according to expected low-density lipoprotein cholesterol (n = 2757)

Using the ESC estimation of LDL-C reductions at discharge after a first STEMI, 38.7% of the cohort would reach LDL-C ≤ 55 mg/dL (≤ 1.4 mmol/L) even under a full dose of statins and total adherence, 16.8% of patients would require ezetimibe, and 44.5% would still have LDL-C above 55 mg/dL (1.4 mmol/L) under statins and ezetimibe and thus be eligible for a PCSK9i without statistical difference between men and women (Figure 4). Using the 2016 guidelines, 14.3% of patients would be eligible for ezetimibe and 22.5% for a PCSK9i for LDL-C levels below 70 mg/dL (1.8 mmol/L).

Control of other cardiovascular risk factors and outcomes

The follow-up of cardiovascular risk factors is displayed in Table 3. Persistent active smoking was frequent and concerned 35% of men and 14% of women. Among diabetic patients, Hb1aC was above 6.5% in 81 (47%) men and 21 (68%) women. The vast majority of patients had a well-controlled blood pressure (72%). During total




Figure 1 Eligibility for primary prevention statins and lifestyle interventions in 2016, 2019, and 2021 European Society of Cardiology guidelines before a first ST-segment elevation myocardial infarction overall (A) and according to sex (B).

follow-up, the composite of ACS, stroke, or death occurred at a rate of 5.1 per 1000 patient-years.

Discussion

Within 5 years, the ESC and EAS have implemented a substantial number of updates in the guidelines: the 2019 ESC/EAS guidelines lowered the LDL-C thresholds to start primary prevention therapy, modified the criteria to be considered at very high risk, and implemented novel intensive lipid-lowering therapy such as PCSK9i on top of statins and ezetimibe, with an objective of LDL-C at 55 mg/dL (1.4 mmol/L) or below. The 2021 ESC guidelines on CVD prevention for clinical practice implemented a new SCORE2 to improve

risk stratification and provide an estimation of both non-fatal and fatal events at 10 years. Based on a cohort of consecutive individuals admitted for a first STEMI, we observed a significant improvement in the detection of high-risk individuals, with a three-fold increase in the eligibility for primary prevention statins. This improvement was especially observed for women, for whom cardiovascular risk was previously underestimated.^{12,13} When analysing the follow-up of risk factors in secondary prevention and a guideline-based step-wise approach, most of the patients were eligible for an increase in statin dosage or for adding ezetimibe, but rarely a PCSK9i despite a vast majority of the patients having persistently high LDL-C levels.

In 2019, the *ESC/EAS Guidelines for the Management of Dyslipidemia* improved the identification of individuals at risk of MI compared with prior guidelines but still failed to assign direct statin therapy to 60%




Figure 2 First low-density lipoprotein cholesterol measured during follow-up after a first ST-segment elevation myocardial infarction according to sex.

of these individuals. This improvement in the identification and treatment of adults who developed MI involved both men and women but was mostly seen in the population of women. Similarly to our findings, MB Mortensen *et al.* also showed an increase in eligibility for primary prevention statins from 15% to 32% in the Copenhagen General Population Study with new European guidelines.¹⁴ Of note, this improvement was particularly driven by the increase in age from 65 to 70 years in the recommendation for statins, which particularly involved women. Despite the improvements to identifying and treating individuals at risk, the 2019 ESC guidelines failed to identify 60% of the patients before their first MI. The first explanation involved the SCORE system itself: pivotal in the management of primary prevention, this algorithm has several well-documented limitations, the first being the estimation of the 'last fatal event' rather than the first non-fatal ischaemic event. The second reason is the use of old epidemiological data from 1986 not reflecting the actual CVD burden and underestimating global or individual risk. Eventually, the restricted age range of the previous SCORE (40–70 years old), prevented an efficient detection of women at risk of cardiovascular disease, for whom the average age of MI in Western Europe is 75 years. Thus, using an updated SCORE2 apprehending both non-fatal and fatal events, the new 2021 ESC guidelines greatly improve the identification and treatment of individuals before they have a first MI, with more than one-third of individuals considered at very high risk and two-thirds directly eligible for statin therapy. Such improvement was made possible via the risk model recalibration, which particularly changed the eligibility for statins for women at risk.

Still, the latest ESC guidelines failed to identify and treat more than one-third of individuals before their first MI. A better implementation of risk modifiers in the decisional algorithms is paramount to better detect and treat high-risk subgroups such as women and young individuals despite their many high-risk features.^{15,16} While the task force listed important, meaningful, and frequent risk modifiers in the women and young individuals of our cohort, such as

social deprivation and chronic immune-mediated inflammatory disorder, none of these criteria were efficiently implemented to guide the decision to prescribe statins. In parallel, improvements in the detection of high-risk patients should be weighted with the necessity to avoid unnecessary exposure to statins, with their potential side effects and health costs. As described by Mortensen *et al.*, the improved sensitivity of the 2019 ESC guidelines compared with 2016 was associated with a reduction in specificity, and thus statin treatment for patients who would have not developed atherosclerotic cardiovascular disease.¹⁴

Within 3 years after their first STEMI, more than 70% of the patients did not meet the LDL-C target of 55 mg/dL (1.4 mmol/L): these patients were mostly treated with low- to moderate-intensity statins and without ezetimibe. Thus, when following the gradual response recommended by ESC guidelines, 26% of individuals would be eligible for ezetimibe and 12% for a PCSK9i after a first event—because more than 60% would be first eligible for an increase in statins before considering such therapies. A low rate of patients eligible for PCSK9is after a first MI based on the guidelines was also found by a previous study in a UK real-world study.¹⁷ In contrast, when using the ESC algorithm to predict the expected follow-up LDL-C, around 17% of patients could be eligible for ezetimibe and 40% for a PCSK9i.

Questions remain regarding the proportion of patients requiring a PCSK9i on top of statins and ezetimibe directly after an ACS to reduce LDL-C levels below 55 mg/dL as recommended by the ESC/EAS. In the EVACS (Evolocumab in Acute Coronary Syndrome) trial, only 23.8% of the patients treated with statins reached the objective of LDL-C \leq 55 mg/dL (\leq 1.4 mmol/L) at 30 days, demonstrating that nearly 80% would be eligible for a PCSK9i; in contrast, LDL-C \leq 55 mg/dL was reached for 65.4% and 90% of patients with a PCSK9i at discharge and 30 days, respectively.¹⁸ In the EVOPACS (Evolocumab for Early Reduction of LDL-cholesterol Levels in Patients with Acute Coronary Syndromes) trial, only 37%




Figure 3 Guideline-based response to low-density lipoprotein cholesterol >55 mg/dL (>1.4 mmol/L) in a real-life setting with comparison of 2016 and 2019/2021 recommendations overall (A) and according to sex (B).

of the patients on statins reached LDL-C < 70 mg/dL at 1 year, highlighting that at least 70% of the patients would need a PCSK9i to reach the recommended goal of 55 mg/dL.¹⁹

Thus, the immediate implementation of PCSK9 after a first STEMI could be the next important step to reduce cardiovascular death or events and enable an effective and rapid reduction in LDL-C levels, especially as evolocumab and alirocumab were associated with a reduction of 15–20% of cardiovascular events, including death.^{20,21} The ongoing AMUNDSEN (Acute Myocardial Infarction Upbound to PCI Immediately or in the Next Three Days and Randomized to Subcutaneous Evolocumab or Normal

Strategies to Reach Guidelines LDL Objectives in the Real-world) trial (NCT04951856) is the largest study to evaluate the direct introduction of evolocumab vs. standard of care in individuals admitted for an ACS. Better strategies are needed to improve the control of cardiovascular risk factors after a first STEMI. Persistent smoking was present in one out of three individuals, and new-onset diabetes in 10% of the population. These results are consistent with the observations of Sverre *et al.*: in a nationwide Norwegian registry of post-MI patients, half of the individuals continued smoking, and 46% with persistent high blood pressure.²² Beyond pharmacological interventions, education about




Figure 4 Eligibility for intensive lipid-lowering therapy after a first myocardial infarction according to 2016 European Society of Cardiology guidelines and 2019/2021 European Society of Cardiology guidelines based on expected follow-up low-density lipoprotein cholesterol.

Table 3 Control of other risk factors during follow-up according to sex

	Overall	Men	Women	P-value	Data (n)
At least one uncontrolled risk factor	381 (39%)	310 (38%)	71 (45%)	0.085	975
Blood pressure control					
Number of drugs	2.00(1.00–2.00)	2.00(1.00–2.00)	2.00(1.00–2.00)	0.76	625
Systolic arterial pressure (mmHg)	130(116–140)	128(116–140)	133(117–144)	0.1	534
Diastolic arterial pressure (mmHg)	75.0(68.0–80.0)	75.0(69.0–80.0)	70.0(65.5–80.0)	0.09	534
PAS > 140 mmHg, n (%)	269 (28%)	217 (27%)	52 (33%)	0.09	975
Diabetes					
HbA1c (%)	6.25 (5.70–7.00)	6.20(5.70–7.00)	6.40(5.60–7.30)	0.33	202
>6.5%, n (%)	102 (50%)	81 (47%)	21 (68%)	0.032	204
Smoking status					
Active smoking, n (%)	86 (31%)	78 (35%)	8 (14%)	<0.01	281

cardiovascular risk and change of lifestyle remain a cornerstone to improve the outcomes of patients admitted with a first STEMI. We demonstrated that lifestyle intervention alone, or before therapeutic intervention, was recommended in most patients before their first STEMI.

Study limitations

The present study contains limitations. First, risk modifiers such as coronary artery calcium score (CACS), carotid plaques, and CT coronary angiography (CTCA) were not collected or used in the algorithms to determine eligibility for statins. As a result, we could have underestimated the proportions of patients eligible for primary

prevention statins, but this also reflects the simple clinical decision tools used in daily practice. Secondly, patients with non-ST-elevation myocardial infarction (NSTEMI) were not analysed in this study, as our cohort only includes STEMI patients. Thirdly, our simulated analysis did not take into consideration individual variations in response to treatments and compliance, which may have led to an overestimation of eligibility. LDL-C levels were measured on samples taken within the hour of admission for STEMI and used as baseline LDL-C, based on studies showing very minimal variations between LDL-C before and after ACS.^{23,24} Tolerance of statins in secondary prevention was not collected to decide whether an increase in the dosage was permitted, leading

to a potential underestimation of patients eligible for ezetimibe and a PCSK9i during follow-up. Eventually, our real-life follow-up LDL-C was incomplete, but our findings were consistent with prior descriptions.

Conclusions

The 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice improve the identification of subjects at risk for a first STEMI compared with the 2019 and 2016 guidelines, in both men and women. However, one-third of individuals admitted for a first STEMI would not have met the criteria provided by the 2021 ESC/EAS guidelines for primary prevention statin therapy. In secondary prevention, a vast majority of patients kept LDL-C levels above the goal of 55 mg/dL, for whom increasing the statin dose and adding ezetimibe were the most frequently recommended therapeutic actions. Ongoing trials are currently challenging this stepwise approach vs. the direct introduction of PCSK9is after a first STEMI.

Supplementary material

Supplementary material is available at *European Heart Journal—Quality of Care and Clinical Outcomes* online.

Funding

Action Study Group.

Conflict of interest: G.M. reports research grants, funding, or consulting fees from Abbott, Amgen, AstraZeneca, Axis, Bayer, BMS, Boehringer Ingelheim, Boston Scientific, Cell Prothera, CSL Behring, Idorsia, Leo Pharma, Lilly, Medtronic, Novartis, Pfizer, Quantum Genomics, Sanofi, and Terumo. M.Z. reports research grants, funding, or consulting fees from Fédération Française de Cardiologie, Institut Servier, BMS/Pfizer, and AstraZeneca. J.S. reports research grants, funding, or consulting fees from AstraZeneca, Bayer HealthCare SAS, Abbott Medical France SAS, Biotronik, Boehringer Ingelheim France, CSL Behring SA, Gilead Science, and Sanofi-Aventis France, and is a stock holder of Pharmaseeds, Terumo France SAS, and Zoll. M.K. reports research grants, funding, or consulting fees from Fédération Française de Cardiologie, du Programme PHRC N, de l'Institut Servier et des honoraires de Bayer, Sanofi, and Servier. P.S. reports research grants, funding, or consulting fees from Amgen, AstraZeneca, Bayer, BMS, Boehringer, Bouchara Recordati, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, Servier, and Vifor. B.L. reports research grants, funding, or consulting fees from Biotronik, Boston Scientific, Daiichi Sankyo, and the Fédération Française de Cardiologie et Institute of CardioMetabolism and Nutrition; and honoraria from Daiichi Sankyo, Eli Lilly, AstraZeneca, Medtronic, and Novartis. J.P.C. reports research grants, funding, or consulting fees from AstraZeneca, Boston Scientific, Bristol Myers Squibb, COR2ED, LeadUp, Medtronic, and WebMD. D.S., P.G., O.B., D.B., E.M., J.P., N.P., and T.S. report no conflicts of interest.

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

References

- Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valmignier M, Vos T, Whelton PK, Yacoub M, Zuhke L, Murray C, Fuster V, GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. *J Am Coll Cardiol* 2020;**76**:2982–3021.
- Kaptoge S, Pennells L, Bacquer DD, Cooney MT, Kavousi M, Stevens G, Riley LM, Savin S, Khan T, Altay S, Amouyel P, Assmann G, Bell S, Ben-Shlomo Y, Berkman L, Beulens JW, Björkelund C, Blaha M, Blazer DG, Bolton T, Beaglehole RB, Brenner H, Brunner EJ, Casiglia E, Chamnan P, Choi Y-H, Chowdry R, Coady S, Crespo CJ, Cushman M, Dagenais GR, Sr RBD, Daimon M, Davidson KW, Engström G, Ford I, Gallacher J, Gansevoort RT, Gaziano TA, Giampaoli S, Grandits G, Grimsgaard S, Grobbee DE, Gudnason V, Guo Q, Tolonen H, Humphries S, Iso H, Jukema JW, Kauhanen J, Kengne AP, Khalili D, Koenig W, Kromhout D, Krumholz H, Lam TH, Laughlin G, Ibañez AM, Meade TW, Moons KGM, Nietert PJ, Ninomiya T, Nordestgaard BG, O'Donnell C, Palmieri L, Patel A, Perel P, Price JF, Providencia R, Ridker PM, Rodriguez B, Rosengren A, Roussel R, Sakurai M, Salama V, Sato S, Schöttker B, Shara N, Shaw JE, Shin H-C, Simons LA, Sofianopoulou E, Sundström J, Völzke H, Wallace RB, Wareham NJ, Willeit P, Wood D, Wood A, Zhao D, Woodward M, Danaei G, Roth G, Mendis S, Onuma O, Varghese C, Ezzati M, Graham I, Jackson R, Danesh J, Angelantonio ED. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. *Lancet Glob Health* 2019;**7**:e1332–e1345.
- Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen M-R, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney M-T, Badimon L, Funck-Brentano C, Agewall S, Barón-Esquivias G, Borén J, Bruckert E, Cordero A, Corsini A, Giannuzzi P, Gueyffier F, Krstacic G, Lettino M, Lionis C, Lip GYH, Marques-Vidal P, Milicic D, Pedro-Botet J, Piepoli MF, Rigopoulos AG, Ruschitzka F, Tuñón J, Eckardstein A von, Vrablik M, Weiss TW, Williams B, Windecker S, Zimlichman R, Zamorano JL, Aboyans V, Achenbach S, Agewall S, Badimon L, Barón-Esquivias G, Baumgartner H, Bax JJ, Bueno H, Carerj S, Dean V, Erol C, Fitzsimons D, Gaemperli O, Kirchhof P, Kolh P, Lancellotti P, Lip GYH, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Roffi M, Torbicki A, Vaz Carneiro A, Windecker S, Zelveian PH, Siostrzonek P, Ibrahimov F, Sujayeva V, Claeys MJ, Pojskic B, Postadzhiyan A, Miličić D, Georgiou GC, Rosolova H, Klausen C, Viigimaa M, Kervinen K, Kedev S, Ferrières J, Petriashvili S, Kintscher U, Rallidis L, Gábor Kiss R, Gudnason T, Maher V, Henkin Y, Mureddu GF, Mussagaliyeva A, Ibrahim P, Mirrahimov E, Latkovskis G, Ben Lamin H, Slapikas R, Visser L, Dingli P, Ivanov V, Wittekoek J, Howland A, Rynkiewicz A, Rato Q, Ezhov M, Zavatta M, Nedeljkovic MA, Pella D, Fras Z, Marzal D, Nilsson L, Mach F, Addad F, Kayikcioglu M, Mitchenko O, Wald D. 2016 ESC/EAS guidelines for the management of dyslipidaemias. *Eur Heart J* 2016;**37**:2999–3058.
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M-R, Tokgozoglu L, Wiklund O, Mueller C, Drexel H, Aboyans V, Corsini A, Doehner W, Farnier M, Gigante B, Kayikcioglu M, Krstacic G, Lambrinou E, Lewis BS, Masip J, Moulin P, Petersen S, Petronio AS, Piepoli MF, Píntó X, Räber L, Ray KK, Reiner Ž, Riesen WF, Roffi M, Schmid J-P, Shlyakhto E, Simpson IA, Stroe E, Sudano I, Tselepis AD, Viigimaa M, Vindis C, Vonbank A, Vrablik M, Vrsalovic M, Zamorano JL, Collet J-P, Koskinas KC, Casula M, Badimon L, John Chapman M, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M-R, Tokgozoglu L, Wiklund O, Windecker S, Aboyans V, Baigent C, Collet J-P, Dean V, Delgado V, Fitzsimons D, Gale CP, Grobbee D, Halvorsen S, Hindricks G, Iung B, Juni P, Katus HA, Landmesser U, Leclercq C, Lettino M, Lewis BS, Merkely B, Mueller C, Petersen S, Petronio AS, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Touyz RM, Nibouche D, Zelveian PH, Siostrzonek P, Najafav R, Borne P van de, Pojskic B, Postadzhiyan A, Kypris L, Špinar J, Larsen ML, Eldin HS, Viigimaa M, Strandberg TE, Ferrières J, Agladze R, Laufs U, Rallidis L, Bajnok L, Gudjonsson T, Maher V, Henkin Y, Gulizia MM, Mussagaliyeva A, Bajraktari G, Kerimkulova A, Latkovskis G, Hamoui O, Slapikas R, Visser L, Dingli P, Ivanov V, Boskovic A, Nazzi M, Visseren F, Mitevska I, Retterstøl K, Jankowski P, Fontes-Carvalho R, Gaita D, Ezhov M, Foscoli M, Giga V, Pella D, Fras Z, Isla LP de, Hagström E, Lehmann R, Abid L, Ozdogan O, Mitchenko O, Patel RS. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the

- Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). *Eur Heart J* 2020;**41**: 111–188.
5. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, Dis I van, Gelder IC van, Wanner C, Williams B, ESC Scientific Document Group, ESC National Cardiac Societies. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). *Eur Heart J* 2021;**42**:3227–3337.
 6. SCORE2 Working Group, ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. *Eur Heart J* 2021;**42**:2439–2454.
 7. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. *J Am Coll Cardiol* 2009;**54**:1209–1227.
 8. Mortensen MB, Falk E. Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention. *Eur Heart J* 2017;**38**:2259–2263.
 9. Guerin M, Silvain J, Gall J, Darabi M, Berthet M, Frisdal E, Hauguel-Moreau M, Zeitouni M, Kerneis M, Lattuca B, Brugier D, Collet J-P, Lesnik P, Montalescot G. Association of serum cholesterol efflux capacity with mortality in patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2018;**72**: 3259–3269.
 10. Silvain J, Kerneis M, Zeitouni M, Lattuca B, Galier S, Brugier D, Mertens E, Procopi N, Suc G, Salloum T, Frisdal E, Le Goff W, Collet J-P, Vicaute E, Lesnik P, Montalescot G, Guerin M. Interleukin-1 β and risk of premature death in patients with myocardial infarction. *J Am Coll Cardiol* 2020;**76**:1763–1773.
 11. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanVagner LB, Wang N-Y, Tsao CV, on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. *Circulation* 2021;**143**: e254–e743.
 12. Zeitouni M, Sabouret P, Kerneis M, Silvain J, Collet J-P, Bruckert E, Montalescot G. 2019 ESC/EAS guidelines for management of dyslipidaemia: strengths and limitations. *Eur Heart J Cardiovasc Pharmacother* 2021;**7**:324–333.
 13. Zeitouni M, Nanna MG, Sun J-L, Chiswell K, Peterson ED, Navar AM. Performance of guideline recommendations for prevention of myocardial infarction in young adults. *J Am Coll Cardiol* 2020;**76**:653–664.
 14. Mortensen MB, Nordestgaard BG. 2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease. *Eur Heart J* 2020;**41**:3005–3015.
 15. Collet J-P, Zeitouni M, Procopi N, Hulot J-S, Silvain J, Kerneis M, Thomas D, Lattuca B, Barthelemy O, Lavie-Badie Y, Esteve J-B, Payot L, Brugier D, Lopes I, Diallo A, Vicaute E, Montalescot G, ACTION Study Group. Long-term evolution of premature coronary artery disease. *J Am Coll Cardiol* 2019;**74**:1868–1878.
 16. Zeitouni M, Clare RM, Chiswell K, Abdulrahim J, Shah N, Pagidipati NP, Shah SH, Roe MT, Patel MR, Jones WS. Risk factor burden and long-term prognosis of patients with premature coronary artery disease. *J Am Heart Assoc* 2020; **9**:e017712.
 17. Elamin AFM, Grafton-Clarke C, Wen Chen K, Obafemi T, Luvai A, Katira R, Davis G. Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: a UK real-world study. *Postgrad Med J* 2019;**95**:61–66.
 18. Leucker TM, Blaha MJ, Jones SR, Vavuranakis MA, Williams MS, Lai H, Schindler TH, Latina J, Schulman SP, Gerstenblith G. Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period. *Circulation* 2020;**142**:419–421.
 19. Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, Muller O, Häner J, Gencer B, Crljenica C, Amini P, Deckarm O, Iglesias JF, Räber L, Heg D, Mach F. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). *J Am Coll Cardiol* 2019;**74**:2452–2462.
 20. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby J-F, Tricoci P, White HD, Zeiher AM. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med* 2018;**379**:2097–2107.
 21. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med* 2017;**376**:1713–1722.
 22. Sverre E, Peersen K, Husebye E, Gjertsen E, Gullestad L, Moum T, Otterstad JE, Dammen T, Munkhaugen J. Unfavourable risk factor control after coronary events in routine clinical practice. *BMC Cardiovascular Disorders* 2017;**17**:40.
 23. Barth JH, Jackson BM, Farrin AJ, Efthymiou M, Worthy G, Copeland J, Bailey KM, Romaine SPR, Balmforth AJ, McCormack T, Whitehead A, Flather MD, Nixon J, Hall AS, SPACE ROCKET Trial Group. Change in serum lipids after acute coronary syndromes: secondary analysis of SPACE ROCKET study data and a comparative literature review. *Clin Chem* 2010;**56**:1592–1598.
 24. Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. *J Am Coll Cardiol* 2008;**51**:1440–1445.

Updates from the American Heart Association Scientific Sessions: cardiovascular pharmacotherapy

Husam M. Salah¹, Allison P. Levin² and Marat Fudim^{3,4,*}

¹Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA; ²Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA; ³Division of Cardiology, Department of Medicine, Duke University, Durham, NC, USA; and ⁴Duke Clinical Research Institute, 2301 Erwin Road, Durham, NC, USA

Received 30 November 2021; accepted 1 December 2021; online publish-ahead-of-print 4 December 2021

Results from highly anticipated pharmacological trials were presented at the American Heart Association (AHA) Scientific Sessions 2021. Herein, we summarize key findings (Table 1).

More evidence favouring sodium–glucose cotransporter 2 inhibitor use in heart failure

A subgroup analysis of the EMPEROR-Preserved trial investigated whether the benefit of empagliflozin seen in heart failure (HF) patients with an ejection fraction (EF) >40% persisted when limited to patients with an EF >50%. In the primary analysis of patients with class II–IV HF and EFs ≥40% randomized to empagliflozin versus placebo, a significant reduction in the primary composite outcome of cardiovascular death and HF hospitalization was seen (event rate 13.8% vs. 17.1%).¹ The subgroup analysis among ‘true’ heart failure with preserved ejection fraction (HFpEF) patients demonstrated a 17% relative reduction in the primary outcome and 22% reduction in first HF hospitalization. In addition, empagliflozin had comparable and significant symptomatic improvement [change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score and New York Heart Association (NYHA) functional class]. Thus, the benefits of empagliflozin were comparable in heart failure with mid-range ejection fraction (HFmrEF) and HFpEF patients.

CHIEF-HF, a novel, virtually conducted randomized trial with no in-person visits, canagliflozin versus placebo in HF patients, found a significant improvement in symptoms among HF patients, regardless of diabetic status or EF (60% HFpEF). The 12-week change in the KCCQ total symptom score (TSS), the study’s primary end-point, was 4.3 points greater with canagliflozin. Additionally, this study demonstrated the feasibility and safety of utilizing virtual technologies in conducting pragmatic/digital trials.

The EMPULSE trial answered a crucial question regarding in-hospital initiation of empagliflozin in patients with acute decompensated HF. Empagliflozin was found to have a significant benefit over placebo with a primary composite outcome of death, number of HF events, time-to-first HF event, and 90-day change in KCCQ TSS, evidenced by a stratified win ratio of 1.36 in favour of the therapy, with no safety concerns.

Omecamtiv mecarbil and stroke risk in systolic heart failure

A secondary analysis of the GALACTIC-HF trial, which randomized patients with symptomatic HF and EF ≤35% to omecamtiv mecarbil or placebo, reported a significant stroke reduction. The therapy reduced the risk of first stroke by 35% (fatal or non-fatal stroke) and fatal strokes by 44%. These findings may be related to the increase in atrial and ventricular contractility and decrease in atrial fibrillation/flutter events seen with this selective cardiac myosin activator.

Milvexian for the prevention of venous thromboembolism

The AXIOMATIC-TKR trial investigated the efficacy and safety of milvexian, an oral factor-Xia inhibitor, in patients undergoing knee arthroplasty. Milvexian was compared with prophylactic dose enoxaparin, and found to have similar effectiveness in venous thromboembolism (VTE) prevention and a low bleeding risk.² Rates of VTE prevention, but not bleeding, were dose-dependent.

* Corresponding author. Tel: 919 684 1284, Fax: 919 613 5145, Email: marat.fudim@duke.edu

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Table 1 Summary of the design and main findings of key late-breaking trials during the American Heart Association Scientific Sessions 2021

Clinical trial	Question	Design	N	Primary outcome	Findings
GIRAF (NCT01994265)	Effect of dabigatran compared with warfarin on cognitive endpoints in patients who are > 65 years old and have atrial fibrillation and a CHADS ₂ /VASC score of > 1	Randomized, single-blind (outcomes assessor), active-controlled, parallel assignment, phase 4 design	200	Cognitive impairment at 2 years independent of cerebrovascular events	No difference between warfarin and dabigatran in Mini-Mental State Exam ($P = 0.75$), Neuropsychological Test Battery ($P = 0.40$), and computer-generated neuropsychological test ($P = 0.06$). Warfarin improved Montreal Cognitive Assessment compared with dabigatran ($P = 0.02$)
EMPEROR-Preserved (NCT03057951)	Efficacy of empagliflozin in patients with heart failure with preserved ejection fraction ($\geq 50\%$)	Secondary analysis of randomized, double-blind, placebo-controlled, parallel assignment, phase 3 design	4005	Cardiovascular death or heart failure (HF) hospitalization	Empagliflozin significantly reduced the primary outcome [hazard ratio (HR) 0.83; 95% confidence interval (CI) 0.71, 0.98]
CHIEF-HF (NCT04252287)	Effect of canagliflozin on Kansas City Cardiomyopathy Questionnaire total symptom score (TSS) in patients with symptomatic HF	Virtual, randomized, double-blind, placebo-controlled, parallel assignment, phase 3 design	476	KCCQ	Canagliflozin significantly improved KCCQ TSS at 12 weeks compared with placebo (mean difference 4.3; $P = 0.016$)
EMPULSE (NCT04157751)	Efficacy and safety of empagliflozin in patients with acute HF	Randomized, double-blind, placebo-controlled, parallel assignment, phase 3 design	530	Composite of death, number of HF events, time to first HF event, and change in KCCQ TSS from baseline to 90 days	Empagliflozin significantly improved the primary outcome [stratified win ratio 1.36; 95% CI (1.09, 1.68)]
PREPARE-IT 2 (NCT04460651)	Efficacy and safety of icosapent ethyl (IPE) on COVID-19-related hospitalizations in non-hospitalized patients with COVID-19	Randomized, double-blind, placebo-controlled, parallel assignment, phase 3 design	2052	COVID-19–related hospitalization	No difference between IPE and placebo on the primary outcome [HR 0.84; 95% CI (0.65, 1.08)]
AXIOMATIC-TKR (NCT03891524)	Efficacy of milvexian, an oral factor Xla inhibitor, in preventing total venous thromboembolism (VTE) events in patients undergoing knee arthroplasty	Randomized, open-label, study drug-dose blind, parallel assignment, phase 2 design	1242	Number of patients with total VTE, defined as the composite of asymptomatic deep-vein thrombosis, symptomatic venous thromboembolism, or death from any cause	Incidence of VTE with twice daily milvexian was 12%, which was significantly lower than the pre-specified benchmark (30%); one-sided $P < 0.001$
REVERSE-IT (NCT04286438)	Effect of benteracimab, a recombinant human IgG1 monoclonal antibody fragment that binds to free ticagrelor, on reversing the antiplatelet effect of ticagrelor and haemostasis parameters in patients presenting with uncontrolled major or life-threatening bleeding or who require urgent surgery/invasive procedure	Multicentre, open-label, prospective single-arm study	150 (enrolment is ongoing in North America and Europe with a goal to include at least 200 patients)	The minimum percentage inhibition of platelet reactivity units (PRUs) within 4 h of benteracimab initiation	Primary reversal endpoint was successfully met (PRU < –50%, $P < 0.001$)

Funding

National Heart, Lung, and Blood Institute (NHLBI) (K23HL151744) and the American Heart Association (20IPA35310955) to M.F.

Conflict of interest: M.F. was supported by the Mario Family Award, Duke Chair's Award, Translating Duke Health Award, Bayer, Bodyport, and BTG Specialty Pharmaceuticals. He receives consulting fees from Abbott, Audicor, Axon Therapies, Bodyguide, Bodyport, Boston Scientific, CVRx, Daxor, Edwards Lifesciences, Feldschuh Foundation, Fire1, Gradient, Intershunt, NXT Biomedical, Pharmacosmos, PreHealth, Splendo, Vironix, Viscardia, and Zoll.

References

1. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner La, Rocca H-P, Choi D-J, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med* 2021;**385**: 1451–1461.
2. Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, Mahaffey KW, Notani RS, Roberts R, Segers A, Raskob GE. Milvexian for the prevention of venous thromboembolism. *N Engl J Med* 2021;**385**:2161–2172.

Management of antithrombotic therapy in patients at high bleeding risk after percutaneous coronary intervention for acute coronary syndromes: a case report

Hamid Mahmood¹, Farhan Shahid ², Mohaned Egred ^{2*}, and Mohamed Farag ³

¹Cardiology Department, Northwest General Hospital and Research Centre, Peshawar, Pakistan; ²Cardiothoracic Department, Freeman Hospital, Newcastle-Upon-Tyne, UK; and

³Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK

Received 12 July 2021; first decision 12 August 2021; accepted 28 May 2022

For the podcast associated with this article, please visit <https://academic.oup.com/ehjcr/pages/podcast>

Background

Choosing antithrombotic therapy for patients at high bleeding risk, particularly those requiring long-term anticoagulant therapy, who have acute coronary syndromes (ACS) and/or undergoing percutaneous coronary intervention (PCI) is becoming increasingly complex.

Case summary

A 78-year-old woman was hospitalized with chest pain and a diagnosis of non-ST-elevation ACS was made. It was decided that the patient should undergo coronary angiogram with a view for angioplasty. Subsequently, she underwent successful PCI to the left anterior descending artery. Shortly after PCI, she was noted to be in atrial fibrillation. Furthermore, she had per rectal bleeding and acute kidney injury, which were managed conservatively. Aspirin and ticagrelor were stopped and she was discharged on dual antithrombotic therapy with clopidogrel and apixaban.

Discussion

Available evidence, driven mainly from expert consensus documents, advocates a case-by-case comprehensive evaluation that integrates patient- and procedure-related factors to assess patients for thrombotic and bleeding tendencies to identify those who may gain most net clinical benefit of antithrombotic combination therapy. In general, if thrombotic drivers prevail, an augmented antithrombotic regime with a view for a longer duration should be planned, and if bleeding drivers prevail, a de-escalated regime with a view for a shorter duration should be sought.

Keywords

Antithrombotic therapy • Acute coronary syndromes • Bleeding • Thrombosis • Case report

ESC Curriculum

3.2 Acute coronary syndrome • 3.1 Coronary artery disease

Learning points

- A one size fits all approach is not ideal for the management of antithrombotic therapy after acute coronary syndromes (ACS).
- In patients with ACS at high bleeding risk, the ultimate goal is to identify a therapeutic window 'sweet spot' of optimal protection and safety, where the combined risk of recurrent thrombosis and bleeding is low.
- After ACS, a dynamic individualized assessment of thrombotic vs. bleeding risks is required as part of a tailored management approach, taking into consideration the patient's preference.

* Corresponding author. Email: mohamedfarag@nhs.net

Handling Editor: Tom De Potter

Peer-reviewers: Rita Pavasini; Claudio Montalto; Joseph Moutiris

Compliance Editor: Rayhan Noah Saiani/Lavanya Athithan

Supplementary Material Editor: Anthony Paulo Sunjaya

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Referencing guideline

Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J.* 2021;42:1289-1367.

Introduction

Patients who suffer from acute coronary syndromes (ACS) and/or undergo percutaneous coronary intervention (PCI) are usually prescribed dual antiplatelet therapy (DAPT, consisting of aspirin and a P2Y₁₂ inhibitor), with an aim to provide secondary prevention strategy and reduce mortality.¹ The commonest reason for the addition of oral anticoagulation (OAC) to DAPT is the coexistence of atrial fibrillation (AF). Of note, one-fifth of patients who have ACS or PCI would warrant such therapeutic regime.¹⁻³ Withholding OAC to reduce bleeding risk may lead to a higher risk of stroke and attempts to reduce DAPT put the patients at risk of stent thrombosis, recurrent myocardial infarction, and even death. Management of patients with ACS and high bleeding risk remains a clinical challenge. This case study highlights the complexity of treating this cohort, and the different treatment strategies currently evidenced to individualize these patients' care.

Timeline

Day 0	Admission with non-ST-elevation acute coronary syndrome and loading doses of dual antiplatelet therapy (aspirin 300 mg and ticagrelor 180 mg) were given
Day 1	Maintenance doses of dual antiplatelet therapy (aspirin 75 mg daily and ticagrelor 90 mg twice daily) were given. A transthoracic echocardiography showed anterior wall hypokinesia with preserved left ventricular systolic function and no significant valvular heart disease
Day 2	Successful percutaneous coronary intervention (PCI) using one drug-eluting stent to the mid left anterior descending artery. A new diagnosis of atrial fibrillation (AF) with controlled ventricular response on a 12-lead electrocardiogram was made shortly after PCI
Day 3	New episodes of per rectal bleeding secondary to haemorrhoids and Grade II acute kidney injury presumed secondary to contrast-induced nephropathy
Day 4	Ticagrelor was de-escalated to clopidogrel 75 mg daily after a loading dose of 600 mg ~24 h after the last dose of ticagrelor
Day 5	No further per rectal bleeding. Apixaban 5 mg twice daily was started
Day 7	Aspirin was stopped and the patient was discharged on dual antithrombotic therapy with clopidogrel 75 mg daily and apixaban 5 mg twice daily for 12 months, then apixaban monotherapy thereafter
3 months	The patient had a good recovery with no major issues highlighted

Short summary of case (hypothetical)

A 78-year-old Caucasian women with a past medical history of hypertension and Type II diabetes mellitus was hospitalized with chest pain and elevated high-sensitivity troponin tests. She was subsequently diagnosed with non-ST-elevation acute coronary syndrome (NSTEMI-ACS). Her admission electrocardiogram (ECG) was unremarkable. She had loading doses of DAPT (aspirin 300 mg and ticagrelor 180 mg), and maintenance doses were prescribed (aspirin 75 mg daily and ticagrelor 90 mg twice daily). Physical examination was unremarkable including cardiovascular examination. She was planned to have an inpatient coronary angiogram with a view for angioplasty within the next 48 h. A transthoracic echocardiography showed anterior wall hypokinesia with preserved left ventricular systolic function and no significant valvular heart disease. On day 2, she underwent successful PCI using one drug-eluting stent to the mid-left anterior descending artery. There was mild diffuse bystander coronary artery disease that was non-flow limiting. Shortly after PCI, she was noted to be in AF with a controlled ventricular response on a 12-lead ECG. Furthermore, she had episodes of per rectal bleeding secondary to haemorrhoids and Grade II acute kidney injury presumed secondary to contrast-induced nephropathy, which were managed conservatively with good recovery.

Whilst in-hospital for 7 days, the patient received maintenance daily doses of aspirin 75 mg and ticagrelor 90 mg. As she remained in AF, ticagrelor was de-escalated to clopidogrel 75 mg daily after a loading dose of 600 mg ~24 h after the last dose of ticagrelor. She was discharged on dual antithrombotic therapy (DAT) with clopidogrel 75 mg daily and apixaban 5 mg twice daily for 12 months, then apixaban monotherapy thereafter. Other medications included a proton pump inhibitor for gastric protection, in addition to a beta-blocker, an angiotensin-converting enzyme inhibitor and a statin. Aspirin was stopped at hospital discharge on Day 7. An outpatient clinic follow-up was carried out at 3 months from index event and no concerns were highlighted.

Discussion

After ACS, while the emphasis is to prevent morbidity and mortality from future ischaemic events, the risk of high bleeding events translating into mortality is receiving recognition.^{1,2} In ACS patients at high bleeding risk (HBR), especially those requiring long-term OAC, the ultimate goal is to reduce the combined risk of recurrent thrombosis and bleeding events. In the subset of patients with NSTEMI-ACS and/or undergoing PCI, and after DAPT loading doses (ideally with aspirin and clopidogrel), current ESC guidelines recommend DAT with clopidogrel and a non-vitamin K oral anticoagulant (NOAC) at the lowest recommended dose for stroke prevention for at least 12 months, and after an initial short period of up to 1 week of triple antithrombotic therapy (TAT, aspirin, and DAT).³ This recommendation is mainly derived from subgroups of randomized controlled trials (Table 1). Of note, subsequent meta-analyses of these trials have demonstrated significantly lower bleeding with DAT compared with TAT with no increase in overall ischaemic events.^{10,11} However, a higher stent thrombosis rate was observed with DAT containing a

Table 1 Randomized controlled trials including patients with non-ST-segment elevation acute coronary syndrome requiring long-term anticoagulation

Study	Population (n)/duration	DES (%)	ACS (%)	AF (%)	Conclusions
WOEST ⁴	573 Between 2008 and 2011	65	27	69	TIMI bleeding and all-cause mortality lower with DAT (VKA + C) vs. TAT (VKA + A + C) at 1 year. No difference in MI, ST, stroke, or TVR
ISAR-TRIPLE ⁵	614 Between 2008 and 2013	99	32	84	No difference in MACE or TIMI major bleeding at 9 months with TAT (VKA + A + C) for 6 weeks followed by DAT (VKA + A) vs. TAT (VKA + A + C) for 6 months followed by DAT (VKA + A)
PIONEER AF-PCI ⁶	2124 Between 2013 and 2015	66	52	100	Clinically significant bleeding, all-cause death and rehospitalization lower with DAT (rivaroxaban 15 mg/day + C for 12 months) or modified TAT (rivaroxaban 2.5 mg b.i.d. + A + C for 1, 6, or 12 months) vs. TAT (VKA + A + C for 1, 6, or 12 months). No difference in cardiovascular death, MI or stroke
RE-DUAL PCI ⁷	2725 Between 2014 and 2016	83	50	100	Major or clinically relevant non-major bleeding lower with DAT (dabigatran 110 or 150 mg b.i.d. + C or T) vs. TAT (VKA + A + C) up to 3 months. No difference in death, MI, stroke, systemic embolism or unplanned revascularization
AUGUSTUS ⁸	4614 Between 2015–2018	NR	37	100	Major or clinically relevant non-major bleeds lower with DAT (apixaban 5 mg b.i.d. + C or T or P) vs. DAT (VKA + C or T or P) or TAT (apixaban 5 mg b.i.d. + A + C or T or P) or TAT (VKA + A + C or T or P). Death and hospitalization lower with apixaban
ENTRUST-AF PCI ⁹	1506 Between 2017 and 2018	NR	52	100	Major or clinically relevant non-major bleeds non-inferior between DAT (edoxaban 60 mg + C or T or P) or TAT (VKA + A + C or T or P). No difference in cardiovascular death, MI, ST, stroke, or systemic embolism

A, aspirin, ACS, acute coronary syndrome, AF, atrial fibrillation, b.i.d., twice a day, C, clopidogrel, DAT, dual antithrombotic therapy, DES, drug-eluting stent, MI, myocardial infarction, NR, not reported, P, prasugrel, T, ticagrelor, ST, stent thrombosis, TAT, triple antithrombotic therapy, TIMI, Thrombolysis In Myocardial Infarction, TVR, target vessel revascularization, VKA, vitamin K antagonist

NOAC and an antiplatelet.^{10,12} It is important to highlight that these studies were primarily designed to assess bleeding events and therefore may have lacked power to provide meaningful results on ischaemic events.

Choice of antiplatelet agent

No trials have evaluated the comparison of DAT containing aspirin vs. a P2Y₁₂ inhibitor. However, an expert consensus document in 2016 recommended P2Y₁₂ inhibitors over aspirin because of their higher efficacy and better gastrointestinal tolerance.¹³ Currently, there is limited data to support the use of DAT containing either ticagrelor or prasugrel after PCI, as clopidogrel was chosen in >90% of cases in available trials. Therefore, the use of ticagrelor or prasugrel as part of TAT should be avoided due to the absence of safety data. In all patients requiring a combination of antiplatelet and anticoagulant therapy, gastric protection with a proton pump inhibitor is recommended.³

Balancing the risk of ischaemia and bleeding after acute coronary syndrome

In ACS patients at HBR and requiring long-term OAC, an expert consensus document in 2018 recommended shortening DAT duration to 6 months by withdrawing the ongoing antiplatelet therapy, especially with newer generation drug-eluting stents.¹⁴ In contrast, for patients at high thrombotic risk requiring long-term OAC, TAT

(aspirin and DAT) is suggested to continue for up to 1 month, followed by DAT for up to 12 months.¹⁴ Recently, the AFIRE randomized trial of 2236 AF patients treated with PCI discouraged the need to continue with a single antiplatelet agent in combination with rivaroxaban beyond 12 months.¹⁵ However, the trial had several limitations with results that are difficult to explain considering the known biologic effects of antithrombotic therapy.

An individualized approach of shortened vs. extended therapy according to patients' combined bleeding/thrombotic risk profile has therefore been advocated and is probably responsible for the wide variation observed in clinical practice.¹⁶

Atrial fibrillation and acute coronary syndromes

Concomitant AF exists in up to 16% of ACS patients with an increased risk of future stroke and death compared to patients without AF. This is mainly due to lack of OAC prescription in those at high risk of thrombosis [i.e. CHA₂DS₂-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes, stroke, vascular disease, age 65–74, sex category female) ≥2].¹⁷ In AF patients with a relatively low stroke risk (CHA₂DS₂-VASc of 1 in men or 2 in women), an expert consensus document in 2016 suggested treating upfront with only DAPT for the first 4 weeks after ACS/PCI,¹ although numerically more myocardial infarction events occurred when aspirin plus clopidogrel were used.¹⁸ Thus, a more potent P2Y₁₂ inhibitor




Figure 1 Therapeutic window of platelet inhibition after acute coronary syndromes. **Bleeding risk** is increased with advanced age, uncontrolled hypertension, Stage ≥ 4 chronic kidney disease, combined antiplatelet and anticoagulant use, prior bleeding events or bleeding tendencies/diathesis, active malignancy, low body weight and anaemia. **Thrombotic risk** is increased with advanced age, uncontrolled hypertension, Stage ≥ 4 chronic kidney disease, diabetes, prior myocardial infarction, acute coronary syndromes, extensive coronary artery disease, prior stent thrombosis, suboptimal stenting, greater stent length, small stent diameter, and bifurcation stenting.

(i.e. ticagrelor or prasugrel) may be preferable in this situation. In AF patients with ACS undergoing coronary artery bypass graft surgery, antithrombotic therapy, preferably with DAT, should be resumed as soon as the post-operative bleeding is controlled.

Identifying the ‘sweet spot’

It is important to highlight that the evidence informing ESC practice guidelines generally reflects population-level data. The lack of a reliable individualized risk stratification tool to assess patients for thrombotic and bleeding tendencies to identify a safe therapeutic window, where the net clinical benefit is the highest, has led to limited use of potent antithrombotic drugs in many patients. However, it is important to note that this therapeutic window is likely variable, factorial and patient-specific.¹³ Extremes of on-treatment platelet reactivity are associated with recurrent adverse events. Patients with high on-treatment platelet reactivity are at risk of thrombotic events, whilst those with low on-treatment platelet reactivity are at risk of bleeding. The ultimate goal of any antithrombotic management regime is to identify a therapeutic ‘sweet spot’ of optimal protection and safety, where the risk of thrombotic and bleeding events is low (Figure 1).

Given the trade-off between ischaemic and bleeding risks for antithrombotic medications, the use of risk stratification scores might be useful to guide individualized prescription. However, such scores have yet to be developed or validated for patients with AF and concomitant ACS/PCI. Several scores are mentioned in current ESC

guidelines.³ To assess the bleeding risk, the PRECISE-DAPT score, enclosing a five-item prediction model (age, creatinine clearance, haemoglobin, white blood cell count and prior spontaneous bleeding), or the ARC-HBR score are recommended, with a high risk identified as PRECISE-DAPT ≥ 25 or the ARC-HBR criteria met.¹⁹ For the latter, patients are considered at HBR if they meet at least one major or two minor criteria. Major criteria included anticipated long-term anticoagulation after PCI, severe, or end-stage chronic kidney disease (eGFR < 30 mL/min), anaemia (haemoglobin < 11 g/dL), spontaneous bleeding requiring hospitalization or transfusion in the previous 6 months or at any time, if recurrent, moderate or severe thrombocytopenia (platelet count $< 100 \times 10^9/L$), chronic bleeding diathesis, cirrhosis with portal hypertension, active malignancy in the previous 12 months, presence of brain arteriovenous malformation, previous spontaneous intracranial haemorrhage (ICH) at any time, previous traumatic ICH in the previous 12 months, moderate or severe ischaemic stroke in the previous 6 months, non-deferrable major surgery on DAPT, major surgery or major trauma in the 30 days before PCI. Minor criteria included ≥ 75 years, moderate chronic kidney disease (eGFR, 30–59 mL/min), haemoglobin 11.0–12.9 g/dL for men and 11.0–11.9 g/dL for women, spontaneous bleeding requiring hospitalization or transfusion in the previous 12 months not meeting the major criterion, long-term use of oral non-steroidal anti-inflammatory drugs or steroids, any ischaemic stroke at any time not meeting the major criterion. The HASBLED (Hypertension,

abnormal renal and liver function, stroke, bleeding history or predisposition, labile INR [international normalized ratio], elderly [>65 years], drugs and alcohol) score of ≥ 3 was also incorporated in the guidelines to identify AF patients at HBR but should not be directly used in patients with AF and ACS/PCI. Available scoring systems are derived mainly from clinical characteristics, which often overlap in predicting the risk (e.g. advanced age, uncontrolled hypertension, and chronic kidney disease). Designing risk stratification tools incorporating clinical, procedural, and rheological biomarkers may perhaps better risk-individualize patients.

The AUGUSTUS trial was the only randomized trial offering insight into the use of NOAC therapy (in the form of Apixaban), without aspirin combination, in patients with AF undergoing PCI.⁸ Apixaban monotherapy resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischaemic events. Such results were very promising in showing a safety and efficacy benefit of NOAC monotherapy vs. regimens that included a vitamin K antagonist, aspirin, or both. There is a need for further trials to stratify patients based on risk prediction models to tailored treatments vs. standard care taking into consideration the thrombotic and bleeding risks, as well as the patient's values and preferences.

High bleeding risk in the elderly

Another HBR cohort, although not limited to, is that of the elderly. Bleeding risk increases with advanced age, with frequent concomitant comorbidities adding another burden to the choice of antithrombotic therapy following ACS/PCI in this cohort. Although the relationship between age and bleeding risk appears to be continuous, one must bear in mind that biological and chronological age are two separate entities and therefore patients should be assessed on an individualized basis with regards to their bleeding risk. Furthermore, one must acknowledge that bleeding risk must be balanced against thrombotic risk and that a balanced approach should guide the duration of antiplatelet therapy after ACS/PCI in this cohort.

Three randomized trials investigating short DAPT durations were completed in patients undergoing PCI perceived to be at increased bleeding risk.^{20–22} In all three trials involving >5000 patients, advanced age was the commonest factor associated with increased bleeding (64% in LEADERS FREE, 51% in ZEUS, and 100% in SENIOR). To this effect, bleeding risk scores have been incorporated to help risk-stratify these patients, in particular the PRECISE-DAPT and the ARC-HBR.³

Conclusions

Patients with ACS requiring long-term OAC are at high risk of bleeding due to the need for combined antithrombotic therapy, as recommended by current practice guidelines, irrespective of whether invasive or conservative approaches are followed. A careful consideration of thrombotic and bleeding risks as well as the patient's preference is warranted to reduce the combined risk of ischaemic and bleeding events. More comparative randomized trials are needed to evaluate the efficacy and safety of antithrombotic therapies to guide clinical decisions.

Lead author biography



Dr Mohamed Farag is a consultant cardiologist, coronary and structural interventions, at the Lister and Hammersmith hospitals, Hertfordshire and London, UK. He holds an honorary academic appointment as a senior clinical lecturer of cardiovascular medicine at the University of Hertfordshire, UK. He qualified in medicine at Ain-Shams University, Cairo, Egypt and undertook cardiovascular training at the world-class Royal Papworth hospital, Cambridge and Freeman hospital, Newcastle. In addition to clinical training, he undertook a period of dedicated research, leading to a postgraduate MSc from the University of Edinburgh and PhD from the University of Hertfordshire, the latter expanded existing knowledge in predicting future heart attacks in high risk patients. He is actively engaged in research with a special interest in coronary thrombosis and risk stratifying heart attack patients.

Consent: Patient consent has been obtained.

Conflict of interest: The authors have no conflict of interest to declare.

Funding: None declared.

Contributor role: All the authors drafted the manuscript and approved the last version submitted.

References

- Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014;**35**:2541–2619.
- Valgimigli M, Costa F, Likhnygina Y, Clare RM, Wallentin L, Moliterno DJ, Armstrong PW, White HD, Held C, Aylward PE, Van de Werf F, Harrington RA, Mahaffey KW, Tricoci P. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. *Eur Heart J* 2017;**38**:804–810.
- Collet JP, Thiele H, Barbatto E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale Paul, Dorobantu M, Edvardsen T, Folliquet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehili J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM, Kastrati A, Mamas MA, Aboyans V, Angiolillo DJ, Bueno H, Bugiardini R, Byrne RA, Castelletti S, Chieffo A, Cornelissen V, Crea F, Delgado V, Drexel H, Gierlotka M, Halvorsen S, Haugaa KH, Jankowska EA, Katus HA, Kinnaird T, Kluin J, Kunadian V, Landmesser U, Leclercq C, Lettino M, Meinila L, Mylotte D, Ndrepepa G, Omerovic E, Pedretti RFE, Petersen SE, Petronio AS, Pontone G, Popescu BA, Potpara T, Ray KK, Luciano F, Richter DJ, Shlyakhto E, Simpson IA, Sousa-Uva M, Storey RF, Touyz RM, Valgimigli M, Vranckx P, Yeh RW, Barbatto E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliquet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehili J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2021;**42**:1289–1367.
- Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermaas AA, Vis MM, Tijssen JG, van't Hof AW, ten Berg JM, WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary

- intervention: an open-label, randomised, controlled trial. *Lancet* 2013;**381**: 1107–1115.
5. Fiedler KA, Maeng M, Mehilli J, Schulz-Schüpke S, Byrne RA, Sibbing D, Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sarafoff N. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. *J Am Coll Cardiol* 2015;**65**:1619–1629.
 6. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Iancu J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. *N Engl J Med* 2016;**375**:2423–2434.
 7. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. *N Engl J Med* 2017;**377**:1513–1524.
 8. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH; AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. *N Engl J Med* 2019;**380**:1509–1524.
 9. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. *Lancet* 2019;**394**: 1335–1343.
 10. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, Valgimigli M. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. *Eur Heart J* 2019;**40**:3757–3767.
 11. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, Granger CB, Verheugt FWA, Li J, Ten Berg JM, Sarafoff N, Gibson CM, Alexander JH. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. *JAMA Cardiol* 2019;**4**:747–755.
 12. Saglietto A, D'Ascenzo F, Errigo D, Leonardi S, Dewilde WJ, Conrotto F, Omedè P, Montefusco A, Angelini F, De Filippo O, Bianco M, Gallone G, Bruno F, Zaccaro L, Giannini F, Latib A, Colombo A, Costa F, De Ferrari GM. Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: a network meta-analysis. *Catheter Cardiovasc Interv* 2021;**97**:581–588.
 13. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: a North American Perspective-2016 Update. *Circ Cardiovasc Interv* 2016;**9**:e004395.
 14. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF, Valgimigli M, Huber K; ESC Scientific Document Group. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). *Europace* 2018;**21**:192–193.
 15. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Antithrombotic therapy for atrial fibrillation with Stable coronary disease. *N Engl J Med* 2019;**381**: 1103–1113.
 16. Bhatt DL, Kaski JC, Delaney S, Alasnag M, Andreotti F, Angiolillo DJ, Ferro A, Gorog DA, Lorenzetti AJ, Mamas M, McNeil J, Nicolau JC, Steg PG, Tamargo J, Tan D, Valgimigli M. Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. *Int J Cardiol* 2021;**337**:1–8.
 17. Jortveit J, Pripp AH, Langørgen J, Halvorsen S. Poor adherence to guideline recommendations among patients with atrial fibrillation and acute myocardial infarction. *Eur J Prev Cardiol* 2019;**26**:1373–1382.
 18. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *Lancet* 2006;**367**: 1903–1912.
 19. Urban P, Mehran R, Collieran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. *Eur Heart J* 2019;**40**:2632–2653.
 20. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, Lipiecki J, Richardt G, Iñiguez A, Brunel P, Valdes-Chavarrí M, Garot P, Talwar S, Berland J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll HP, Morice MC; LEADERS FREE Investigators. Polymer-free drug-coated coronary stents in patients at high bleeding risk. *N Engl J Med* 2015;**373**:2038–2047.
 21. Valgimigli M, Patilias A, Thury A, McFadden E, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airolidi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. *J Am Coll Cardiol* 2015;**65**:805–815.
 22. Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, Hovasse T, Garot P, El Mahmoud R, Spaulding C, Helft G, Diaz Fernandez JF, Brugaletta S, Pinar-Bermudez E, Mauri Ferre J, Commeau P, Teiger E, Bogaerts K, Sabate M, Morice MC, Sinnaeve PR; SENIOR investigators. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. *Lancet* 2018;**391**:41–50.

The ADVANCED CONTROL TRIAD for every matter of the heart...



Rely on the potent *triple drug combination*

In hypertension uncontrolled on dual therapy

Rx **Telma[®]-ACT**

Telmisartan 40 mg + Amlodipine 5 mg + Chlorthalidone 6.25/12.5 mg

 **Advanced Control Triad**

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only

Abbreviated Prescribing Information: Telma ACT: Telmisartan 40 mg + Amlodipine 5 mg + Chlorthalidone 6.25mg/12.5mg.

Active Ingredients: Telma ACT - contains Telmisartan 40 mg plus amlodipine 5 mg plus chlorthalidone 6.25mg/12.5mg. **Indication:** For the treatment of essential hypertension. **Dosage and Administration:** Dosage must be individualised. Telma ACT should be used once daily with or without food. **Contraindications:** Known hypersensitivity to either telmisartan or amlodipine or chlorthalidone, severe hepatic or renal dysfunction, pregnancy and lactation, patients with anuria. **Warning and Precautions:** Caution required in severe hepatic and renal impairment, and in volume depleted patients. In heart failure, monitoring required for worsening of heart failure. Should be used with caution in patients with renal disease or with impaired hepatic function and monitoring of renal function is recommended. Hyperuricemia may occur or frank gout may be precipitated. **Use in Pregnancy & Lactation:** For telmisartan, pregnancy category is C for first trimester and D for second and third trimester. Excretion in human milk is unknown. With thiazides, there is risk of foetal and neonatal jaundice, and thrombocytopenia. Telma ACT should be discontinued immediately if the patient becomes pregnant. **Adverse Drug Reactions:** Headache, dizziness, hypotension, cough, nausea, upper respiratory tract infection, weakness, anorexia, cramping and peripheral oedema.

ABPI Ref.: Telma ACT /1-Jan-2022

For further product-related query, contact at Glenmark Pharmaceuticals Limited (GPL), Medical Services, Corporate Enclave, B. D. Sawant Marg, Chakala, Andheri (E), Mumbai - 400099. E-mail id: globalcustomerservice@glenmarkpharma.com

For any Adverse Event or Product Quality Complaint related to Glenmark marketed products, contact on globalcustomerservice@glenmarkpharma.com

Disclaimer: For the use of a registered medical practitioner or a hospital or a laboratory only.

PVCCODE: TELMAACT/ADVERT/16052022/1027

ZOLTANMAX
A Division of **glenmark**

- **Become a member**
and access webinars **for free**



- Interactive courses
 - Live discussions with Key Opinion Leaders
 - Online assessment
-
- Check upcoming sessions
on **www.escardio.org/Webinars**